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1.1 Stem cells 
Stem cells have the remarkable potential to differentiate into specialized cells and thereby 
are key factors for the development of the whole organism. All types of stem cells share their 
unique ability for self-renewal while maintaining their undifferentiated state and the potential 
to undergo differentiation into diverse and more restricted progeny. All tissues and organs of 
the body are derived from cascades of stem cells, which become more and more restricted in 
differentiation potential the further through development they arise. A new organism starts as 
a totipotent fertilized egg, which starts to divide, forming after several divisions the blastocyst. 
The outer layer consists of the trophoblast, giving rise to the placenta, while the inner cell 
mass forms all three germ layers of the embryo. The cells of the inner cell mass, known as 
embryonic stem cells, can be extracted and cultured in vitro, and are able to generate any 
cell type of the mature organism in vitro (Smith, 2001; Thomson et al., 1998). For this reason, 
embryonic stem cells are termed pluripotent, while unipotent stem cells can only form a 
single lineage (Weissman, 2000). During embryonic development, a program called 
neurogenesis, composed of complex patterns of sequential cycles of symmetrical and 
asymmetrical division of neural stem cells, establishes the complex structure of the brain 
(Breunig et al., 2011; Kriegstein and Alvarez-Buylla, 2009; Noctor et al., 2001; Rakic, 1988; 
Reynolds and Weiss, 1992; Urbach et al., 2004). Neural stem cells of this process can give 
rise to neurons and glia, the two lineages most cells of the central nervous system belong to, 
and are therefore called multipotent. In the adult human brain, the hippocampus and the 
subventricular zone (SVZ) are the only brain areas with residual neural stem cell populations 
(Eriksson et al., 1998; Gage, 2000). This might suggest that most parts of the human brain 
cannot be regenerated after neurogenesis is completed, with fatal consequences for patients 
in case of disease or injury. 
The ability to generate all cell populations of the human body by harnessing human 
pluripotent stem (hPS) cells to reconstruct diseased or injured tissue has become a major 
focus in regenerative medicine (Lovell-Badge, 2001). Moreover, the development of human 
stem cell-based disease models represents a newly born research area and has received 
much attention (Colman and Dreesen, 2009; Han et al., 2011). Neuronal tissue from patients 
is not readily available, and most cells in the central nervous system are post-mitotic, which 
renders them unsuitable for genetic modifications. However, the use of patient-derived stem 
cell populations offers an unlimited source of cells and the potential to derive the cell type of 
interest together with the possibility to enrich for genetic modifications during the dividing 
stem cell state. 
 2 
1.1.1 Human pluripotent stem cells 
Landmark discoveries of the young field of human stem cell science were the isolation and 
culture of inner cell mass from human blastocysts by Bongso in 1994 and in the derivation of 
the first hES cell lines reported by Thomson and coworkers in 1998 (Bongso et al., 1994; 
Thomson et al., 1998). These achievements opened the field, which has seen constant 
improvements in the derivation and maintenance of hES cells since then (Kim et al., 2005; 
Marteyn et al., 2011; Strelchenko et al., 2004). In classical protocols, hES cells are cultured 
as colonies in a coculture system with growth-inhibited mouse embryonic feeder cells in 
medium containing FGF2 and fetal bovine serum, while newer protocols have improved 
towards chemically defined media and synthetic xeno-free substrates that meet GMP 
requirements, a prerequisite if cells are to be used for therapeutical application (Chen et al., 
2011b; Klimanskaya et al., 2005; Rodin et al., 2010). Analysis of the molecular 
characteristics of hES cells helped to decipher the mechanisms of pluripotency (Cartwright, 
2005; Chambers et al., 2003; Li, 2005; Niwa et al., 1998; Rodda et al., 2005; Takasugi et al., 
2003). In 2006 these efforts culminated in the discovery of induced pluripotency (iP) by 
Takahashi and Yamanaka, who demonstrated that adult somatic cells can be directly 
reprogrammed into pluripotent stem cells by retroviral overexpression of only four 
transcription factors that were previously discovered as key regulators of the embryonic stem 
cell state (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). The resulting induced 
pluripotent stem, or iPS, cells appear to have the same characteristics of self-renewal and 
differentiation potential as hES cells (Gore et al., 2011; Hussein et al., 2011; Lister et al., 
2011). Since the discovery of induced pluripotency, reprogramming technology developed 
rapidly towards safer methods such as using integration-free techniques like direct protein 
transduction, mRNA, or the use of Sendaivirus and mature microRNA transfection as well as 
by reducing the number of transcription factors and even replacing them with chemical 
compounds (Anokye-Danso et al., 2011; Ban et al., 2011; Kim et al., 2009; Miyoshi et al., 
2011; Nakagawa et al., 2008; Warren et al., 2010; Zhu et al., 2010). The emergence of iPS 
cell technology revolutionized the stem cell field as it not only avoids the ethical and legal 
issues connected to hES cell research, but also implies the generation of any cell type from 
any individual in unlimited quantities. For regenerative medicine approaches and the 
investigation of disease mechanisms, the key challenge for stem cell research will be to find 
protocols for efficient differentiation of pluripotent cells in vitro into authentic somatic cell 
types. 
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1.1.2 In vitro differentiation potential of human pluripotent and neural stem cells 
By translating knowledge from developmental neurobiology, protocols to generate distinct 
neural cell types from pluripotent cells have been established. Pluripotent stem cells 
represent the most immature stem cell population that is capable of neurogenic 
differentiation. In the earliest protocols that were established, the founding pluripotent cells 
were sequentially exposed to a cocktail of morphogens to directly guide them into a mature 
neural cell type. When the self-renewal promoting environment of pluripotent stem cells is 
withdrawn, a large portion of them ultimately form neurons and glia, which led to the 
impression of a ’neuro-by-default’ mechanism (Carpenter et al., 2001; Muotri et al., 2005; 
Reubinoff et al., 2001; Thomson et al., 1998; Tropepe et al., 2001). Drawbacks of these early 
protocols are the relatively long time spans required, especially with slowly dividing human 
cells, as well as batch-to-batch variations, which may result in a different outcome for each 
single experiment. Distinct from such so-called ‚run-through’ protocols are those using an 
emerging stable neural stem cell population as a well-defined intermediate. A variety of 
multipotent neural stem cells from human pluripotent cells with differing potential have been 
reported and can be aligned to specific stages of human neurodevelopment (Conti and 
Cattaneo, 2010). 
Early neuroepithelium precursor cells spontaneously convert into metastable rosette 
neuroepithelial stem (r-NES) cells that depend on SHH and Notch agonists when kept in 
culture for a few passages (Elkabetz et al., 2008). These cells express the transcription-
factors PLZF and Dach1, form characteristic rosette structures with apical ZO1 expression 
and show interkinetic nuclear migration qualifying them as an in vitro reflection of early neural 
tube forming cells (Abranches et al., 2009; Elkabetz et al., 2008; Zhang et al., 2001). When 
exposed to the mitogens FGF2 and EGF in addition to B27 supplement mix, a homogenous 
and stable rosette-type long-term self-renewing neuroepithelial stem cell population (lt-NES 
cells) can be generated (Koch et al., 2009; Nemati et al., 2010). Caudalizing morphogenic 
activity of FGF2 (Cox and Hemmati-Brivanlou, 1995; Mason, 1996) and retinoic acid from the 
B27 mixture might explain the observed anterior hindbrain phenotype of lt-NES cells, which 
is, however, responsive to other instructive morphogens (Cox and Hemmati-Brivanlou, 1995; 
Glaser et al., 2005; Koch et al., 2009; Mason, 1996). This cell population may overcome 
many of the limitations described for hES cells, also because they can be extensively 
propagated for at least 150 passages and display a stable neurogenic differentiation pattern 
over the passages. In comparison to hESC, these cells exhibit significantly shorter doubling 
times (38 vs. 51-81 hours) and a higher clonogenicity. Moreover, lt-NES cells have been 
shown to be readily amenable to genetic manipulation, e.g. by electroporation or viral 
transduction (Koch et al., 2009; Ladewig et al., 2008).  
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1.2 Candidate diseases for therapeutic intervention  
Organic diseases can roughly be divided into two groups: those of genetic origin and those of 
idiopathic origin. A genetic disease itself can be based on a single mutation, which disrupts 
the function of a protein, or on the combination of many different alterations, which alone may 
never result in a phenotype, but in interplay with other contributors can lead to a disease 
state. The advent of stem cell technology offers new possibilities on the one hand in 
understanding the reasons for disease, for example by generating in vitro the affected tissue 
from patient-derived pluripotent cells and using it in disease studies. On the other hand, it 
also opens the field for possible therapeutic applications by correcting a known disease-
associated phenotype in cell culture and bringing the healthy cells back to its donor. If a 
disease is based on a known genotype like a mutation in a specific gene, a correction of the 
affected sequence into a physiological version should effect in a cure. More complicated is 
the cure of diseases that are either linked to a very complex genotype with several involved 
loci, or without a known genetic reason at all. In this case, the understanding of physiological 
processes within the biochemical network affected allows the deduction which enzymes 
could be modified to positively influence the disease. Hence, genetic modification can be 
beneficial in both cases of genetic and idiopathic diseases. For the application of genetically 
modified lt-NES cells, candidate diseases for both kinds of disorders were evaluated. In the 
following section, two neurological disorders are described: First the monogenetic disorder 
Machado-Joseph-Disease and second the large group of idiopathic epilepsies. Additionally, 
possible points of genetic interactions are shown. 
 
1.2.1 Machado-Joseph-Disease or Ataxia type 3 
Machado-Joseph-Disease (MJD) is an autosomal dominant neurodegenerative disease of 
late onset and the most frequent form of ataxia in humans (Schöls et al., 2004; Schöls et al., 
1995). Originally described in and named after two families of emigrants from the Azorean 
islands based on the clinical phenotype (Nakano et al., 1972; Rosenberg et al., 1976), 
genetic testing later showed that MJD and the spinocerebellar ataxia of type 3 (SCA3) are 
based on the same gene defect (Haberhausen et al., 1995). It originates from an expansion 
of CAG repeats in exon 10 of the ATXN3 gene, which leads to an elongated polyglutamine 
(polyQ) tract of its gene product ataxin-3 in its c-terminus (Kawaguchi et al., 1994). Length of 
the CAG tract is negatively correlated with disease onset (Maciel et al., 1995; van de 
Warrenburg et al., 2002), which affects predominantly cerebellar, pyramidal, extrapyramidal, 
motor neurons and oculomotor systems (Coutinho and Andrade, 1978; Rosenberg, 1992). 
Although the central nervous system is the place of all pathological processes in MJD, 
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ataxin-3 is not only expressed in neural tissue, but ubiquitously all over the body (Ichikawa et 
al., 2001). Several genetic studies found the physiological range of CAG repeats in the 
ATXN3 gene to be up to 47 and the expanded repeat size in patients to be at least 45 (Dürr 
et al., 1996; Matilla et al., 1995; Padiath et al., 2005). As repeat length in both populations 
overlap, the number of CAG repeats alone does not always indicate susceptibility to the 
disease, a phenomenon that has also been shown for other polyQ diseases like Huntington 
(Brinkman et al., 1997). 
 
1.2.1.1 The functional role of ataxin-3 
Ataxin-3 is composed of a globular N-terminal Josephin domain (JD) followed by a flexible C-
terminal tail (Masino et al., 2003). The JD bears ubiquitin protease activity while the tail has 
two ubiquitin interaction motifs, followed by the polyQ region. Inhibiting the deubiquitinating 
activity results in an increase of polyubiquitinated proteins similar to the result of proteasome 
inhibition (Berke et al., 2005). Functional analysis has shown interaction with proteins of the 
proteosomal protein degradation pathway like Rag23 and VCP (Doss-Pepe et al., 2003; 
Wang et al., 2000b). Rag23 itself interacts with the proteasomal subunit S5a (Hiyama et al., 
1999; Ryu et al., 2003) suggesting a role in the shuttling of proteins into the proteasome for 
degradation. This system is especially responsible for the degradation of misfolded proteins 
labeled by ubiquitination, and called ERAD (endoplasmatic reticulum-associated 
degradation), leading to the export into the cytosol for degradation by the proteasome 
(Burnett et al., 2003; Wang et al., 2006; Wang et al., 2004)). It is not yet clear if ataxin-3 
promotes or decreases degradation via this pathway and it could function either as a 
modulator via ubiquitin-modification to ensure degradation or associate with the proteasome 
for substrate recognition (Boeddrich et al., 2006; Wang et al., 2008). Another likely role for 
ataxin-3 is in quality control, as it is reported to be involved in aggresome formation. These 
structures are formed from misfolded proteins at the microtubule-organizing center (MTOC) 
when the proteasome itself cannot use them, leading to their transfer into lysosomes. Ataxin-
3 seems to be involved in the regulation and formation of aggresomes as it co-localizes with 
pro-aggresomes (Burnett and Pittman, 2005; Markossian and Kurganov, 2004). It has been 
further proposed that ataxin-3 is responsible for the transport and stabilization of misfolded 
proteins to the MTOC as it interacts with parts of the cytoskeleton and transport proteins 
(Mazzucchelli et al., 2009; Rodrigues et al., 2010). It is very likely that interaction with 
cytoskeletal proteins is not only restricted to aggresome formation as there is evidence for a 
role of ataxin-3 in morphology and adhesion of the cell (Rodrigues et al., 2010). For example, 
absence prevents cytoskeletal maturation needed for myogenesis (do Carmo Costa et al., 
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2010). Through its C-terminal domain, ataxin-3 does interact with several transcription 
factors and histones, influencing gene expression (Evert et al., 2006; Li et al., 2002). So far, it 
is not clear if this is a direct interaction or if ataxin-3 modifies the turnover rate and thus 
duration of action of the affected transcription factors. The different roles of ataxin-3 and its 




Figure 1.1: Physiological roles of ataxin-3. 
Activity, interactions and roles of ataxin-3 proposed to date. It displays deubiquitinating (DUB) activity 
(A), and interacts with polyUB chains (B). Ataxin-3 was also shown to participate in protein 
homeostasis via ERAD (C). Additionally, roles in formation of aggresomes (D) and cytoskeletal 
interactions have been described (E) as well as regulation of histone acetylation and transcriptional 
regulation (F). Taken from Matos et al. (2011). 
 
 
1.2.1.2 Biochemical properties of aberrant-elongated ataxin-3 
Ataxin-3 has a normal molecular weight of 42 kD, but with enlarged CAG repeats can 
become significantly larger, which confirms that the repeat is translated into a polyQ stretch. 
An important histological hallmark of MJD is intranuclear inclusion bodies in neuronal cells 
(Fig. 1.2b) (Zoghbi and Orr, 2000). These inclusions are large protein aggregates containing 
ataxin-3 along with many other proteins such as proteasomal subunits and transcription 
factors. Recent evidence supports the idea that these aggregates result from cellular 
protective mechanisms against the toxicity of the expanded protein oligomers (Arrasate et al., 
2004; Ross and Poirier, 2004; Shao and Diamond, 2007; Slow et al., 2005). Additionally, 
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toxicity of the expanded CAG repeat of the mRNA transcript has been shown (Li et al., 2008). 
PolyQ-elongated ataxin-3 influences many cellular processes by hindering transcription 
(McCampbell et al., 2000), disturbing the quality control system (Ferrigno and Silver, 2000), 
impairing axonal transport (Gunawardena et al., 2003) and facilitating aggregation of several 
ubiquitinated proteins (Donaldson et al., 2003) due to the loss of proper physiological ataxin-
3 function or blocking of interaction partners (Fig. 1.2a). PolyQ proteins generally tend to 
form aggregates and due to their histological visibility and their predisposition to involve other 
protein species as well in these complexes, investigation has focused on understanding how 
ataxin-3 can aggregate. Overexpression of polyQ-elongated ataxin-3 causes amyloid-like 
fibrils (Bevivino and Loll, 2001), but in overexpression models, the non-expanded variant and 
the JD alone can also form aggregates (Chow et al., 2004; Gales et al., 2005; Masino et al., 
2004). Additionally, mouse models overexpressing expanded human ataxin-3 did not show 
any phenotype, while a strong pathology similar to human patients could be seen in models 
overexpressing only the expanded CAG fragment of human protein (Ikeda et al., 1996). 
Aggregation kinetics in the normal variant seems to be very slow and when interacting with 
different binding partners, ataxin-3 is unlikely to form these complexes. In contrast, the 
expanded variant seems to form more quickly and the resulting aggregates are more stable, 
leading, over decades, to the disease in patients. One important question is, as ataxin-3 is 
present in all tissues, why does its elongation specifically lead to a neuronal disease? 
The development of new cellular models of MJD is crucial for the understanding of how the 
described biochemical alterations finally lead to the incurable loss of neurons. By using MJD-
patient-specific induced pluripotent stem cell-derived neural stem cells, our group found a 
possible mechanism for aggregate formation and why neurons are the cell population of 
disease action (Koch et al., 2011). Proteolytic cleavage of highly aggregation-prone polyQ 
fragments of ataxin-3 has been proposed to trigger the formation of aggregates. The 
formation of early aggregation intermediates is thought to have a critical role in disease 
initiation, but the precise pathogenic mechanism operating in MJD has remained elusive. It 
was found that glutamate-induced excitation of patient-derived neurons initiates Ca2+-
dependent proteolysis of ataxin-3 followed by the formation of SDS-insoluble aggregates. 
This phenotype could be abolished by calpain inhibition, confirming a key role of this 
protease in ataxin-3 aggregation (Fig. 1.2c). Aggregate formation was further dependent on 
functional Na+ and K+ channels as well as ionotropic and voltage-gated Ca2+ channels, and 
was not observed in the founding stem cells, fibroblasts or glia, thereby providing an 
explanation for the neuron-specific phenotype of the disease. This data also illustrates that 
neural stem cells enable the study of aberrant protein processing associated with late-onset 




Figure 1.2: Mechanisms of ataxin-3 toxicity. 
a. PolyQ-expanded ataxin-3 leads to MJD but the responsible mechanisms are still under debate. The 
conformational changes causes by the polyQ stretch may disturb the biologic function of ataxin-3, 
thereby compromising the protein homeostasis system, the cytoskeleton or hindering transcription. 
Aggregation of whole protein or toxic fragments of proteolytic cleavage by calpains can lead to 
membrane destabilization and the impairment of protein sequestration mechanisms. All this 
interference with cell function finally leads to cell death. Adapted from Matos et al. (2011). b. Ataxin-3 
immunoreactive neuronal intranuclear inclusion bodies are a result of the aggregate forming process. 
Adopted from Riess et al. (2008). c. Proposed model of excitation-induced aggregate formation in 
neurons involving activation-dependent Ca2+ influx via voltage-gated Ca2+ channels and subsequent 




1.2.2 Epilepsy associated with different neurological disorders 
Epilepsy is a common set of chronic neurological disorders affecting ~1% of the population, 
and characterized by seizures (Jallon, 1997). It is characterized by changes in the equilibrium 
between excitatory (glutamatergic) and inhibitory (GABA-ergic) neurotransmission. 
Dysfunction of anticonvulsant or neuroprotective regulatory systems have also been reported 
(DeLorenzo et al., 2007). The process that transforms a healthy brain into an epileptic brain, 
such as status epilepticus or traumatic brain injury, is called epileptogenesis, and is triggered 
by initial precipitating injuries (Delorenzo et al., 2005; Prince et al., 2012). Although some 
monogenetic epilepsies are known, most of which are based on ion channel defects, most 
cases are idiopathic. Often a cause cannot be identified despite several potential causative 
factors such as  trauma, strokes, cancer or drug misuse (Chang and Lowenstein, 2003). 
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Currently used antiepileptic drugs largely act on targets involved in neurotransmission to 
suppress seizures, but do not suppress the process of epileptogenesis (Löscher and 
Schmidt, 2006). Surgical interventions also act only symptomatically (Engel, 1996). So far, no 
effective prophylaxis or pharmacotherapeutic cure is available. Additionally, the progression 
to chronic epilepsy often leads to pharmacoresistance and intractable seizures, by which up 
to 30% of all patients with epilepsy are affected (Jallon, 1997). These patients are often 
severely disabled and have an increased risk of sudden death. Thus, new therapeutic 
strategies are needed. A prerequisite for the development of new therapies is the 
understanding of mechanisms underlying epilepsy. 
 
1.2.2.1 Adenosine balance in the central nervous system 
Epilepsy can be seen either as an increased activation or a decreased inhibition of neuronal 
circuits. Therefore, the basal mechanism of activation and inhibition should be examined to 
understand which kind of deregulation leads to seizures. Adenosine acts as a 
neurotransmitter in the brain through the activation of four distinct G-protein-coupled 
receptors that mediate neuroprotection and a general down-regulation of neuronal activity 
(Lombardo et al., 2007). Hence, adenosine itself is thought to act as an endogenous 
anticonvulsant (Beutler, 1993; Fredholm et al., 2005a; Roberts et al., 1994). So far, four 
adenosine receptors have been identified: high-affinity inhibitory A1 and excitatory A2A 
receptors and low-affinity A2B and A3 receptors. Different affinities of these receptors to 
adenosine and variable distribution within the brain form a highly complex system of 
adenosine action (Dunwiddie and Masino, 2001; Fredholm et al., 2005b). The anticonvulsant 
functions of adenosine are thought to base largely upon the activation of A1 receptors 
coupled to inhibitory G proteins leading to an inhibition of the release of neurotransmitters, in 
particular glutamate. The excitatory A2A receptors appear to be restricted to active synapses 
and modulate the action of other neurotransmitters (Ferré et al., 2005). The role of the low 
affinity receptors is not completely understood so far, but all four adenosine receptors can 
form heterodimers with other G-protein coupled receptors, thereby influencing a large 
regulatory network (Sebastião and Ribeiro, 2009). 
Adenosine acts as a fast endogenous response during events of overshooting activity, as its 
release is upregulated during seizures in human patients and during pharmacologically 
induced seizures in rats (Berman et al., 2000; During and Spencer, 1992). Mimicking this 
response by administrating adenosine can moderate epilepsy, but despite optimal drug 
treatment, seizures persist in ~35% of patients with partial epilepsy (Devinsky, 1999). When 
administered systemically, adenosine and its analogues cause strong effects ranging from 
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sedation to suppression of cardiovascular functions and cessation of spontaneous motor 
activity (Dunwiddie, 1999). A local administration of adenosine only in the affected brain 
region would be favored. 
 
1.2.2.2 The role of adenosine kinase 
The enzyme adenosine kinase (also known as ATP:adenosine 5’-phosphotransferase, ADK; 
EC 2.7.1.20) catalyzes the phosphorylation of adenosine to adenosine monophosphate 
(AMP) (Irion et al., 2007) (Fig. 1.3a) and thus plays a key role in the regulation of intra- and 
extracellular adenosine levels. Adenosine is also metabolized by adenosine deaminase, but 
ADK is considered to be the key enzyme due to its lower Km value. This has been further 
validated by inhibition of the ADK, resulting in an increase in synaptic adenosine, which in 
turn suppresses glutamatergic excitatory synaptic transmission (Etherington et al., 2009; Lee 
et al., 1984). Astrogliosis, a pathological hallmark in several epilepsies in patients, is often 
accompanied by overexpression of ADK and resulting adenosine deficiency (Li et al., 2007a). 
Also, in chemically induced spontaneous seizures in animal models, an increase in the 
enzymatic activity of ADK has been detected (Gouder et al., 2004). Thereby deregulated 
ADK provides a molecular link between astrogliosis and neuronal dysfunction in epilepsy. In 
line with this, the viral overexpression of ADK in the hippocampus alone was sufficient to 
trigger seizures (Theofilas et al., 2011). 
The importance of ADK for adenosine levels in the brain has led to a strong interest in using 
this enzyme as a therapeutic target. Local administration of adenosine was assessed by 
implantation of an adenosine releasing synthetic polymer that released low adenosine 
concentrations and protected against electrically induced seizures with no detectable side 
effects in animals (Boison et al., 1999). Such low concentrations should also be producible 
by biological sources. The Boison group developed a system of adenosine-releasing 
fibroblasts with inactivated adenosine kinase and adenosine deaminase. These cells were 
transplanted into brain ventricles in a rat epilepsy model and were shown to efficiently 
suppress seizures (Huber et al., 2001). 
The study of Huber and colleagues used cells engineered by undirected mutagenesis 
comprising a high risk of oncogenic potential. Also, fibroblasts are not a natural population of 
the brain, so a neural cell type with a specifically altered genotype was demanded. This was 
achieved by engineering murine embryonic stem cells by genetic disruption of both alleles of 
the ADK and subsequent differentiation into neural precursor cells by the laboratories of 
Brüstle and Boison (Fedele et al., 2004; Li et al., 2007b). These cells were transplanted into 
rats where they differentiated in vivo into neurons and integrated into the host tissue. This 
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population efficiently suppressed epileptogenesis through adenosine release, while a control 
cell population of baby hamster kidney cells with the same destruction of the ADK gene did 
not show similar benefits after transplantation, underlining the importance of functional 





Figure 1.3: Adenosine kinase function and locus. 
a. The most important metabolizing enzymes of adenosine are adenosine kinase (ADK) and 
adenosine deaminase (ADA). Exchange of intracellular adenosine with extracellular compartments is 
performed via equilibrative nucleoside transporter (ENT). b. Zinc finger nucleases (ZFN) are synthetic 
fusion proteins of a DNA-binding zinc finger domain and a double strand break-inducing nuclease 
domain. Dimerization of nuclease domains is necessary for target cleavage. The cellular machinery for 
non-homologous end joining (NHEJ) is involved in repairing the double strand break, a mechanism 
that is error-prone and can thus result in disruption of the target gene. c. Locus of the ADK gene with 
exons in red and introns in white. The catalytic core around Asp316 is situated at the C-terminal end of 
the protein. Introduction of frame shifts within a coding exon of the gene prior to the catalytic part leads 
to destruction of all enzymatic activity. Also shown is the reaction in which Arg316 attacks adenosine 





This study investigates the use of site-specific disruption of the ADK gene using zinc finger 
nucleases (ZFN, Fig. 1.3b) on a human multipotent neural stem cell population. For the 
targeting approach, the constitution of the gene locus is of importance. Essential for the 
enzyme function is its active site: Asparagine 316 acts as a catalytic base that deprotonates 
the 5’-hydroxyl of adenosine to initiate the transfer of phosphate from ATP to form AMP (Fig. 
1.3c). Substitution of this residue inactivates the enzyme. The C-terminus forms local 
secondary structures constituting the adenosine-binding site (Schumacher et al., 2000), and 
its disruption is accompanied by loss of ADK activity. The gene consists of 11 exons with 
lengths of 36 to 765 bp, the majority having a length below 100 bp (Fig. 1.3c). The 
collaboration partner Sangamo® provided three different ZFNs for targeting exon 5 of the 
ADK gene. Induction of a double-strand break and subsequent frame shifting would result in 
a disrupted gene, whose protein product would be without all enzymatic activities. 
 
1.3  Gene targeting in human cells 
Genetic techniques that specifically change endogenous genes are called gene targeting 
(Thomas and Capecchi, 1987). The term is normally used for modifications that are achieved 
by homologous recombination, and allows removal or addition of whole genes or the 
modification of exons or introduction of point mutations. Targeting implies its specificity to 
target uniquely in the genome, in contrast to random integration of genetic material, e.g. for 
overexpression studies. In model organisms, gene targeting is often achieved by altering the 
germ line to raise whole animals with a modified genome. For the creation of such animals, 
Mario Capecchi, Martin Evans and Oliver Smithies were awarded the Nobel Prize in 
medicine in 2007. Pluripotent stem cells are the major cell source for targeting approaches. 
Although a huge knowledge was accumulated by the use of model organisms, which are 
often susceptible to transformation into the corresponding genes in humans, the limited 
extrapolation potential to other species or cell types constrains such studies. This applies 
especially to the study of higher brain functions and its disorders in humans due to its 
significantly higher complexity, other metabolism or protein composition. However, in 
mammalian cells, non-homologous recombination is more frequent (Waldman, 1992). 
Although there are several methods for enrichment available, such as positive-negative 
selection, where antibiotic resistance is combined with a suicide-enzyme like HSV-TK only 
integrating at off-target-sites (Mansour et al., 1988), or promoterless vectors (Hanson and 
Sedivy, 1995), which in theory are fail-safe, many of them improve the specificity at 
surprisingly low rates in practice (Bunz, 2002). 
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Targeting efficacy is of particular importance for human cells because, unlike in the mouse 
system where a heterozygous targeting event can be bred to homozygosity, the generation 
of homozygously altered human cell lines requires the targeting of both alleles. For a 
homologous recombination with acceptable efficiencies, plasmid lengths of several kb are 
needed (Rubnitz and Subramani, 1984). Because of the high number of single-nucleotide 
polymorphisms in the human genome (Wang et al., 1998) isogenic DNA should be used, 
which would necessitate a customization for each cell line used.  
Transformed tumor cell lines are readily available and easy to handle but offer a very artificial 
model to study the natural function of human genes, while primary cell lines are themselves 
limited to a definite number of passages in cell culture, leaving only a small time window and 
a small population for experiments. Established human embryonic stem (ES) cell lines that 
can be kept in culture theoretically for an unlimited number of passages, offer the possibility 
to establish stable, genetically modified human cell lines. The widespread arrival of induced 
pluripotent (iPS) cells free of ethical controversies now offer the generation of patient-specific 
stem cells that can be differentiated into affected cell types. This will greatly facilitate the 
understanding of biochemistry and physiology of disease-associated genes.  
So far gene manipulation in human cells remains inefficient which aggravates the 
development of disease models or therapeutic applications. Homologous recombination-
mediated genome modification has been used experimentally for decades in yeast while its 
use in mammalian cells was limited by its low spontaneous rate (Porteus and Baltimore, 
2003; Sedivy and Sharp, 1989). Nonetheless, gene targeting has been used as an extremely 
important tool in murine embryonic stem cells. Pioneers in this field were the groups of 
Capecchi and Smithies (Doetschman et al., 1988; Thomas and Capecchi, 1987), which were 
awarded the Nobel Prize in physiology in 2007 for the generation of transgenic mice by 
transferring such modified ES cells into blastocysts. By using this strategy, thousands of 
mouse models have been derived.  
Up to now, only few approaches for genetic modification of human ES cells have been 
reported. Zwaka and co-workers were the first to achieve a homologous recombination in the 
HRPT1 locus in human ES cells using a reporter construct for clone selection (Zwaka and 
Thomson, 2003). However, the reported efficiencies are low compared to standard 
efficiencies in the mouse system. This may be due to the fact that human ES cells are much 
more sensitive to physical manipulations resulting in low survival and clonogenicity. A few 
months later, Urbach and co-workers targeted the same locus to introduce a mutation found 
in Lesch-Nyhan disease into the HRPT1 gene, which for the first time established a model for 
a human-specific disorder in a hES cell-derived culture system (Urbach et al., 2004). 
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The fact that since the first description of human embryonic stem cell lines in 1998 (Thomson 
et al., 1998) only few groups were able to report homologous recombination in the human 
system emphasizes limitations and difficulties of classical gene targeting approaches. Other 
approaches to overcome technical limitations have been developed in the past years. These 
include viral systems like adeno-associated virus (AAV) (Khan et al., 2010) and helper-
dependent adenoviral vectors (HDAdV) (Suzuki et al., 2008) as well as BACs (Song et al., 
2010) or synthetic fusion proteins of nucleases with zinc finger or TALEN domains (Cermak 
et al., 2011; Lombardo et al., 2007) and the recently discovered, RNA-guided Crispr/Cas9-
system (Mali et al., 2013). 
 
1.3.1 Viral systems for gene delivery 
One possibility to enhance the poor rate of homologous recombination events in human cells 
is to use tools optimized by nature for gene delivery: viruses. The direct application of viral 
vectors always bears the danger of unwanted random integration into the genome, which can 
lead to a transformation of single cells into a malignant state (Hackett et al., 2007). One 
single transformed cell already has the potential to form a tumor and up to now, no 
integrative viral system is known that would lack this attribute. Therefore, efforts switched to 
use monoclonal cell populations simplifying screening procedures used to detect unwanted 
alterations (Noda et al., 1986). 
First attempts to repair mutations in genes with retroviral vectors showed high frequencies of 
correction and thus successful targeting, but was also associated with unwanted gene 
conversion in other regions and random integration typical for retroviruses (Ellis and 
Bernstein, 1989). Other studies used modified adenoviral vectors with large homologous 
portions, which deliver their genome with high efficacy and at preferred ratios of correct 
targeting to random insertion, i.e. 1:2.5 (Mitani et al., 1995). They offer a genetic size of over 
30 kb, which allows a flexible selection of homologous parts and the integration of a large 
amount of genetic information, but making the design of targeting vectors difficult. Also, new 
helper-dependent vectors no longer contain toxic viral elements responsible for immune 
responses and their side effects reported for adenoviruses (Christ et al., 1997; Nunes et al., 
1999). Much easier to engineer due its smaller vector size but also with high integration 
efficiencies are Adeno-associated viral (AAV) particles. 
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1.3.2 Recombinant adeno-associated virus type 2 for site-specific targeting 
The adeno-associated virus (AAV) is a member of the parvovirus family, the only human 
virus family with a linear single-stranded DNA genome identified so far. They belong to the 
smallest viruses known and bear a relatively small genome of around 5000 bases (Chapman 
and Rossmann, 1993) Nine subtypes (AAV 1-9) are known, for which humans are the 
primary host, subtype 2 being the most common. While 80% of the human population are 
seropositive, no pathology is associated with the virus (Vasileva and Jessberger, 2005). 
The genome of AAV-2 contains two open reading frames (ORFs), called cap (3 transcripts) 
and rep (4 transcripts) (Srivastava et al., 1983) These coding sequences are flanked on both 
sides by palindromic inverted terminal repeats (ITRs) that form hairpin loops. The rep ORF 
encodes proteins that are involved in viral replication and integration, while the cap genes are 
responsible for packaging and cell infection. Heparan sulphate proteoglycan (HSPG) has 
been shown to act as the primary receptor (Summerford and Samulski, 1998) while αVβ5 
integrin and human fibroblast growth factor receptor 1 have been proposed as co-receptors 
(Qing et al., 1999; Summerford et al., 1999). This enables AAV-2 to infect a large variety of 
cell types including epithelial cells, skeletal muscle, neurons and mesenchymal stem cells 
(Flotte et al., 1992; Kaplitt et al., 1994; Stender et al., 2007; Wang et al., 2000a). 
A lytic infection with production of new AAV particles by the infected cells is dependent on a 
co-infection with an adeno virus, which acts as a helper virus for the AAV due to the 
presence of the immediate early genes E1, E2A, E3 and E4 of adeno virus in the affected 
cells (Richardson and Westphal, 1981). Without these gene products, AAV-2 enters a 
lysogenic cycle, i.e. without the production of virus particles, and stably integrates in the 
human genome. This integration is random, but with a high prevalence for a specific region 
on chromosome 19q13.3, called AAVS1 (Kotin et al., 1992). Presumably, homology in the 
ITRs with this locus is responsible for the preference. For stable integration, the rep 
transcripts are essential. After infection with the suitable helper virus, AAV can again enter 
the lytic cycle. 
Due to its defective replication, the non-pathogenicity and its ability for site-specific 
integration in chromosome 19, AAV2 was considered potentially useful for gene therapy 
approaches that used the addition of functional genes into a “safe harbour” (Linden et al., 
1996). The sequences between the ITRs could be replaced by desired genes and so 
integrated into a passive site of the genome without the danger to impede active genes. 
Soon, vector systems were established, which supplied the rep and cap ORFs needed for 
vector production as well as helper-virus elements in trans. 
Because of its small genome of only 4.8 kb, this vector system is not suitable for large genes. 
Also the danger of a randomized insertion persists, and even when inserted into the main 
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locus at chromosome 19, an influence on cellular genes lying nearby, like the MBS85, was 
reported (Tan et al., 2001). Insertions were observed mainly at transcriptionally active sites 
(Nakai et al., 2003) which can also bear oncogenic potential (Miller et al., 2002). These 
problems seemed to restrict the use of AAV2 as a tool for adding genes to the genome. 
Nevertheless, AAVs were used in attempts to treat Duchenne muscular dystrophy 
(Athanasopoulos et al., 2004) or beta-thalassemia (Tan et al., 2001) where non-dominant 
negative mutations could be compensated by the integration of wild-type genes into the 
AAVS1 locus. The use of AAVs was further simplified by the arrival of commercially available 
systems. 
Following the hypothesis that homology of the ITRs with the AAVS1 locus is responsible for 
preferred respective insertion of AAV genomes, Russell and colleagues used a recombinant 
AAV containing genomic sequences to establish an area of homology in the vector for 
directing the site of integration (Russell and Hirata, 1998). They disrupted the human HPRT 
gene by introducing a mutation of a few base pairs while the total length of homology 
between the substrate and the targeting vector was 2.7 kb. This was about four times less 
than the length required for efficient targeting with conventional systems. Correct integrations 
were about two orders of magnitude higher than observed with adenoviral or retroviral 
vectors (Ellis and Bernstein, 1989). It has been shown that the cellular homologous 
recombination machinery is required for this site-specific gene targeting (Vasileva et al., 
2006). 
As the HPRT gene is situated on the X-chromosome and male cells were used, a selection 
marker was not required and instead a suicide metabolite could be applied. For normal 
biallelic genes another targeting design was necessary. By reducing the homology to 900 bp 
on both sites flanking the target sequence, the system has also been shown to work 
efficiently by disrupting a gene in a human colon cancer cell line (Kohli et al., 2004). This 
system used rAAVs with homology arms laying directly inwards from both ITRs to direct the 
insertion to a specific site. The gained space in the vector of 2.5 kb was employed to 
incorporate a selection marker. From there onwards, two AAV based vector systems were 
established that have to be clearly distinguished. First, the gene adding system for 
integration into the AAVS1 locus on chromosome 19, for which commercial systems are 
available. This system only requires the ITRs in the targeting vector and bears a capacity of 
~4.5 kb. Second, a site-specific system that relies on homology arms inside the ITRs of 
together 1.8 kb length, reducing the available space for a selection cassette to ~2.5 kb. 
The Russell group showed the functionality of this new system for the first time in vivo by 
correcting a mutant lacZ gene at the ROSA26 locus in mouse (Miller et al., 2006). Gene 
correction and gene deletion are possible with the AAV system, each shown in cell culture on 
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transformed cells and in vivo with somatic cells, respectively. However, until now this system 
has not been used on human somatic cells in a cell culture system. For neurons and glia, 
AAV application was reported to be stable and non-toxic when insertion into AAVS1 locus 
was used for gene addition (Howard et al., 2008). These observations suggest that human 
neural stem cells (lt-NES cells), being precursors of glia und neurons were also suitable 
candidates for transduction. 
 
1.3.3 Alternative systems for genetic modifications of human cells 
Besides the already listed viral and electroporation systems, other methods for genetic 
manipulations, or corrections have been described. These include homologous integration, 
which was reported for short double- or single-stranded DNAs (Colosimo et al., 2001), and 
also for DNA/RNA chimeras (Kmiec, 1999) and triplex forming oligos (Fox, 2000). These 
approaches work well and very efficiently for the substitution of only a few base pairs, but are 
not applicable to larger portions of the genome. Therefore they could be used for gene 
correction purposes, but presumably not delivery of whole genes. Also, AAV vectors have 
size limitations, albeit showing a high targeting efficiency. A completely different approach is 
the use of bacterial artificial chromosomes or BACs, which are large circular DNA elements 
up to several megabases in size that can bear several genes and also show a high specificity 
for site-directed targeting due to the large amount of homology they provide. One of the 
major drawbacks is the difficulty to produce and engineer such large constructs, and special 
techniques are needed. For the investigation of disease models, as well as for a possible 
therapeutic application, a system is required that is highly efficient in targeting the desired 
locus, easy to engineer so that it can be used for different approaches, and applicable to 
human stem cells. For the application of patient-specific cells, as well as for use with different 
cell lines, a targeting vector with a relatively short homology region is preferable, so that a 
once constructed vector can be used with cells other than those of isogenic origin. 
 
1.3.4 Zinc finger nuclease targeting 
A relatively new method showing high specificity for the desired locus on the one hand and 
only needing a relatively small recognition sequence on the other hand, are zinc finger 
nucleases (ZFN). Chandrasegaran and coworkers developed the first of these by fusing the 
nonsequence-specific cleavage domain of the FokI restriction endonuclease domain to a new 
DNA-binding domain (Kim et al., 1996). The first DNA-binding domain used was a fruit fly 
homeobox domain, followed by zinc-finger DNA binding domain and yeast Gal4 DNA-binding 
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domain (Kim and Chandrasegaran, 1994; Kim et al., 1998). Further optimization was 
performed by Bibikova et al. (2001), finding cleavage was most efficient when binding sites 
were inversely oriented, separated by six nucleotides and without a peptide linker between 
DNA-binding and nuclease domain. Additionally, these experiments were the first using living 
cells of Xenopus laevis and proved activation of the ZFN substrate for homologous 
recombination by cellular mechanisms. Until then, all DNA-binding domains used were of 
natural origin and thus targeted their known recognition site. The special appeal of ZFN 
however is the possibility to modify the DNA-binding domain to bind specifically chosen 
target sequences, allowing an induced double strand break at a defined position. 
Zinc finger modules are part of the DNA-binding domain of one of the largest families of 
transcription factors in eukaryotic genomes (Diakun et al., 1986). Already in the human 
genome there are more then 4000 different modules in 700 proteins present (Jantz et al., 
2004; Notarangelo et al., 2000). Each module forms a finger of 30 amino acids size binding 
to a 3 bp sequence of DNA and each finger binds its target site independently (Pavletich and 
Pabo, 1991). Combining individual fingers with different triplet targets changes the overall 
binding specificity of the zinc finger protein. The naturally occurring fingers with known 
binding preference were disassembled to find fingers for all 64 different target triplets to 
enable the generation of zinc finger domains binding to any target sequence possible (Pabo 
et al., 2001; Segal and Barbas, 2001; Segal et al., 2003; Wolfe et al., 2000). Despite modules 
for specific sequence blocks being known, there is no general assembly code for the 
generation of consistently high affinity binding of zinc fingers. This makes screening of zinc 
finger domain libraries necessary to optimize their specificity. 
A double strand break per se cannot be termed gene targeting, because it is defined as the 
exchange of DNA in a specific locus by homologous recombination. However, if a frame shift 
resulting in a gene knockout is induced, the outcome is of the same quality; a specific gene 









1.4 Aim of this study 
Apart from the substantial progress made in the last years using human stem cell 
populations for the study of disease mechanism- and progression or their application in cell 
therapeutic paradigms, the majority of studies still focuses on pluripotent populations that 
require time-consuming run-through protocols resulting in populations with a bias for batch-
to-batch variations. As viable alternatives, intermediate stem cell populations, which are 
closer to the cell type of interest but still have the advantages of unlimited self-renewal in 
culture, like the lt-NES cells used in this study could be employed. 
To test the proficiency of lt-NES cells for different applications aiming for disease-modeling or 
therapeutic approaches, straightforward genetic manipulation is essential. This study 
employs different methods exhibiting site-specific genetic intervention to overcome common 
problems of overexpression of proteins or microRNAs. Using gene-editing methods to modify 
endogenous genes in a specific, site-directed manner should have great benefits compared 
to aforementioned techniques, where random integration can lead to genomic instability or 
tumorigenesis, while gene knockdowns by microRNA may be incomplete.  
The present study combines the advantages of a stable somatic intermediate stem cell 
population with multiple approaches of site-specific genetic manipulation. Two examples 
were chosen to address the question: First, exchange of elongated polyQ alleles in the 
ATXN3 gene for disease modeling in vitro to permit comparison of effects and mechanisms 
using isogenic cell lines. Second, the disruption of the adenosine kinase (ADK) gene as a 
basis for cell-mediated activity-dependent adenosine delivery. 
In Machado-Joseph-Disease-patient derived neural stem cells, the polyQ-elongated protein 
variant is causative for the disease and its depletion/deletion or genetic correction should 
result in a cell population with normalized biochemical characteristics. For the site-specific 
exchange of the pathogenic allele of ataxin-3 against its wildtype variant an approach using 
the ability of adeno-associated viruses for site-specific targeting was designed. The resulting 
isogenic populations only differing in one specific locus should offer a better control 
population for elucidating disease mechanism than studies using controls generated from 
relatives.  
Adenosine kinase is a key enzyme for the metabolization of adenosine in the brain and its 
depletion increases adenosine efflux of affected cells. By application of zinc-finger nucleases 
specific for the human adenosine kinase gene, a biallelic knockout to generate an adenosine-
releasing cell population for cell therapeutic approaches is intended. Adenosine itself acts as 
a suppressor of neuronal activity and was shown to moderate epilepsy. Cells with 




































2.1  Technical equipment 
Appliance Name Manufacturer Registered office 
Autoclave D-150 Systec Wettenberg, Germany 
Balance BL610 Sartorius Göttingen, Germany 
Balance LA310S Sartorius Göttingen, Germany 
Block heater Thermomixer compact Eppendorf Hamburg, Germany 
Bone drill 0.7 mm burrs Micro Drill Fine Science Tools Hamburg, Germany 
Centrifuge (large) Megafuge 1.0R Kendro Hanau, Germany 
Centrifuge (table top) 5415D Eppendorf Hamburg, Germany 
Concentrator Speed Vac 5301 Eppendorf Hamburg, Germany 
Counting chamber Fuchs-Rosenthal Faust Halle, Germany 
Cryostat CL6000 Leica Dresden, Germany 
Digital camera C 5050 Zoom Olympus Optical Hamburg, Germany 
Digital camera Powershot G5 Canon Krefeld, Germany 
Electroporator Nucleofector 2b Lonza Basel, Switzerland 
Fluorescence lamp HAL100 Carl Zeiss Jena, Germany 
Fluorescence microscope Axioskop 2 Carl Zeiss Jena, Germany 
Freezer -80°C HERAfreeze Kendro Hanau, Germany 
Gel electrophoresis 




puller PE-21 Tritech Research Los Angeles, USA 
Imaging system Chemidoc 2000 Bio-Rad München, Germany 
Imaging system Geldoc EZ Bio-Rad München, Germany 
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Appliance Name Manufacturer Registered office 
Incubator HERAcell Kendro Hanau, Germany 
Inverse light 
 microscope Axiovert 25 Carl Zeiss Jena, Germany 
LED light source Colibri 2 Carl Zeiss Jena, Germany 
Liquid nitrogen store MVE 611 Chart Industries Burnsville, USA 
Microliter pipet 1710N Hamilton Bonaduz, Switzerland 
Microscope Axiovert 40 CFL Carl Zeiss Jena, Germany 
Microscope Axiovert 200M Carl Zeiss Jena,Germany 
Microscope camera Axiocam MRM Carl Zeiss Jena, Germany 
Micro-Spectrophotometer Nanodrop ND-1000 
Thermo Fisher 
Scientific Wilmington, USA 
Micropipettes 
Labmate L2, 
L10, L20, L100, 
L1000 
Labmate Langenfeld, Germany 
PAGE/Blot equipment Mini-Protean 3 Bio-Rad München, Germany 
pH-meter CG840 Schott Mainz, Germany 
Pipette-boy Accu-Jet Brand Wertheim, Germany 
Power supply for 
electrophoresis 
Standard Power 




 4°C /-20°C G 2013 Comfort Liebherr Lindau, Germany 
Shaker Bühler WS10 Johanna Otto Hechingen, Germany 
Secure horizontal flow 
hood HERAsecure Kendro Hanau, Germany 
Southern blotter Turbo Blotter Carl Roth Karlsruhe, Germany 
Sterile laminar flow hood HERAsafe Kendro Hanau, Germany 
Stereo microscope STEMI 2000-C Carl Zeiss Göttingen, Germany 
Stereotactic Frame Stereotactic Frame Stoelting Illinois, USA 






Appliance Name Manufacturer Registered office 
Table centrifuge Centrifuge 5415R Eppendorf Hamburg, Germany 











Vacuum pump Vacuubrand Brand Wertheim, Germany 
Vortex mixer Vortex Genie 2 Scientific Industries New York, USA 
Water bath 1008 GFL Burgwedel, Germany 
Water filter Millipak 40 Millipore Eschborn, Germany 
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2.2  Plastic ware 
Consumables Manufacturer Registered Office 
6-well culture dishes 
Nunclon surface Nunc Wiesbaden, Germany 
12-well culture dishes 
Nunclon surface Nunc Wiesbaden, Germany 
24-well culture dishes 
Costar Corning Life Sciences Schiphol-Rijk, The Netherlands 
48-well culture dishes 
Costar Corning Life Sciences Schiphol-Rijk, The Netherlands 
Cell Strainer 40 µm Nylon BD Falcon Bedford, USA 
Cryovials 1 ml Nunc Wiesbaden, Germany 
Cryovials 1.8 ml Nunc Wiesbaden, Germany 
PCR strip tubes 0.2 ml peqLab Erlangen, Germany 
Petri dishes ∅ 3.5 cm BD Biosciences Heidelberg, Germany 
Petri dishes ∅ 6 cm BD Biosciences Heidelberg, Germany 
Petri dishes ∅ 10 cm PAA Pasching, Austria 
Round bottom tubes - 
 12x75 mm BD Biosciences Heidelberg, Germany 
Serological pipettes 1 ml BD Falcon Bedford, USA 
Serological pipettes 2ml Corning Life Sciences Schiphol-Rijk, The Netherlands 
Serological pipettes 5 ml Corning Life Sciences Schiphol-Rijk, The Netherlands 
Serological pipettes 10 ml Corning Life Sciences Schiphol-Rijk, The Netherlands 
Serological pipettes 25 ml BD Biosciences Heidelberg, Germany 
Syringes 20 ml BD Biosciences Heidelberg, Germany 
Syringe filter 0.2 µm Pall Dreieich, Germany 
Syringe filter 0.2 µm PALL Dreieich, Germany 
TC dishes ∅ 3.5 cm PAA Pasching, Austria 
TC dishes ∅ 6 cm PAA Pasching, Austria 
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Consumables Manufacturer Registered Office 
TC dishes ∅ 10 cm PAA Pasching, Austria 
Tubes 0.5 ml Greiner Bio-One Solingen, Germany 
Tubes 1.5 ml Greiner Bio-One Solingen, Germany 
Tubes 15 ml Greiner Bio-One Solingen, Germany 
Tubes 50 ml Greiner Bio-One Solingen, Germany 
 
2.3  Chemicals 
Chemicals Manufacturer Registered office 
2-Mercaptoethanol Invitrogen Karlsruhe, Germany 
30% Bis/Acrylamide Carl Roth Karlsruhe, Germany 
8-Chloroadenosine Enzo Lörrach, Germany 
8-Cl-cAMP Enzo Lörrach, Germany 
Agar Sigma Deisenhofen, Germany 
Agarose PeqLab Erlangen, Germany 
Ampiciline Sigma Deisenhofen, Germany 
APS, 10% Sigma Deisenhofen, Germany 
Atipamezol Pfizer Berlin, Germany 
Azide Sigma Deisenhofen, Germany 
B-27 supplement Invitrogen Karlsruhe, Germany 
Bone wax Fine Scientific Tools Heidelberg, Germany 
Bromphenol blue Sigma Deisenhofen, Germany 
BSA solution (7.5%) Sigma Deisenhofen, Germany 
CaCl2 Sigma Aldrich Deisenhofen, Germany 
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Chemicals Manufacturer Registered office 
cAMP Sigma Aldrich Deisenhofen, Germany 
Carprofen Pfizer Berlin, Germany 
Chemiluminescent 
Substrates Thermo Scientific Frankfurt, Germany 
Chloroform Sigma Deisenhofen, Germany 
Chloroquin Sigma Aldrich Deisenhofen, Germany 
Collagenase IV Sigma Aldrich Deisenhofen, Germany 
Complete ULTRA™ tablets Roche Diagnostics Basel, Swizerland 
CytocoonTM Buffer II Evotec Technologies Hamburg, Germany 
Cytoseal Microm Walldorf, Germany 
DABCO Sigma Aldrich Deisenhofen, Germany 
DAPI Sigma Deisenhofen, Germany 
DAPT Sigma Aldrich Deisenhofen, Germany 
Diazepam Roche Basel, Switzerland 
Direct PCR Lysis Reagent PeqLab Erlangen, Germany 
DMEM/F12 (1:1) Invitrogen Karlsruhe, Germany 
DMEM high glucose Invitrogen Karlsruhe, Germany 
DMSO Sigma Deisenhofen, Germany 
DNA ladder (100bp) PeqLab Erlangen, Germany 
DNA ladder (1kb) PeqLab Erlangen, Germany 
dNTPs PeqLab Erlangen, Germany 
Doxycycline Sigma Aldrich Deisenhofen, Germany 
EDTA Sigma Deisenhofen, Germany 
EGF R&D Systems Wiesbaden, Germany 
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Chemicals Manufacturer Registered office 
EHNA Sigma Deisenhofen, Germany 
Eosin Y solution Sigma-Aldrich Deisenhofen, Germany 
Ethanol Merck Darmstadt, Germany 
Ethidium bromide Sigma Deisenhofen, Germany 
FCS Invitrogen Karlsruhe, Germany 
Fentanyl Roche Basel, Switzerland 
FGF2  R&D systems Wiesbaden, Germany 
Ficoll-400 DL Sigma Deisenhofen, Germany 
Flumazenil Roche Basel, Switzerland 
Formic acid Sigma Deisenhofen, Germany 
G418 solution Sigma Deisenhofen, Germany 
Gelatine Invitrogen Karlsruhe, Germany 
Glucose Sigma Deisenhofen, Germany 
L-Glutamate Sigma Deisenhofen, Germany 
L-Glutamine Invitrogen Karlsruhe, Germany 
Glycerol Sigma Deisenhofen, Germany 
HCl Sigma Aldrich Deisenhofen, Germany 
Hematoxylin solution Mayer’s Sigma Aldrich Deisenhofen, Germany 
HEPES Sigma Aldrich Deisenhofen, Germany 
Insulin Sigma Deisenhofen, Germany 
Isopropanol Sigma Aldrich Deisenhofen, Germany 
Kainic acid Sigma Deisenhofen, Germany 
Ketamine Pfizer Berlin, Germany 
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Chemicals Manufacturer Registered office 
Laminin Sigma Deisenhofen, Germany 
Matrigel (MG) BD Biosciences Heidelberg, Germany 
Meditomidin Novartis Nürnberg, Germany 
Methylscopolamine Sigma Deisenhofen, Germany 
Midazolam Roche Basel, Switzerland 
Moviol Sigma Aldrich Deisenhofen, Germany 
N2 supplement (100x) Invitrogen Karlsruhe, Germany 
NaCl Sigma Aldrich Deisenhofen, Germany 
NaHCO3 Sigma Deisenhofen, Germany 
Naloxon Roche Basel, Switzerland 
NaOH Sigma Aldrich Deisenhofen, Germany 
Neurobasal medium Invitrogen Karlsruhe, Germany 
Non-essential amino acids Invitrogen Karlsruhe, Germany 
Opti-MEM basal media Invitrogen Karlsruhe, Germany 
PBS Invitrogen Karlsruhe, Germany 
PFA Sigma Deisenhofen, Germany 
Phenol Sigma Deisenhofen, Germany 
PhosSTOP™ tablets Roche Diagnostics Basel, Swizerland 
Pilocarpine Sigma Deisenhofen, Germany 
Poly-L-ornithine Sigma Deisenhofen, Germany 
RIPA buffer Sigma Aldrich Deisenhofen, Germany 
RNAiMAX Invitrogen Karlsruhe, Germany 
Roti-Block 10% Carl Roth Karlsruhe, Germany 
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Chemicals Manufacturer Registered office 
SDS Sigma Aldrich Deisenhofen, Germany 
Serum Replacement Invitrogen Karlsruhe, Germany 
Sodium pyruvate Invitrogen Karlsruhe, Germany 
Sucrose (60%) Carl Roth Karlsruhe, Germany 
TEMED Sigma Aldrich Deisenhofen, Germany 
Tissue-Tek Weckert Labortechnik Kitzingen, Germany 
Tris Merck Darmstadt, Germany 
Triton-X-100 Sigma Aldrich Deisenhofen, Germany 
Trypane Blue Invitrogen Karlsruhe, Germany 
Trypsin inhibitor (TI) Invitrogen Karlsruhe, Germany 
Trypsin-EDTA (10x) Invitrogen Karlsruhe, Germany 
Tryptone Sigma Deisenhofen, Germany 
VectaShield mounting 
medium Axxora Loerrach, Germany 
Xylene Cyanole FF Bio-Rad München, Germany 
Yeast extract Sigma Deisenhofen, Germany 
 
2.4 Enzymes 
Enzyme name Manufacturer Registered office 
Alkaline Phosphatase, 
Shrimp Roche Diagnostics Penzberg, Germany 
DNase (cell culture) Cell Systems Troisdorf, Germany 
DnaseI (mol. Bio.) Invitrogen Karlsruhe, Germany 
Phusion High Fidelity 
Polymerase Finnzymes Heidelberg, Germany 
Platinum Taq DNA 
Polymerase High Fidelity Invitrogen Karlsruhe, Germany 
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Enzyme name Manufacturer Registered office 
T4 DNA Ligase New England Biolabs Frankfurt, Germany 
Taq DNA Polymerase, 
recombinant Invitrogen Karlsruhe, Germany 
  
2.5 Restriction endonucleases 
2.6 Cell lines and animals 
Cell line or mouse strain Source 
E. coli DH5a Invitrogen, Karlsruhe, Germany 
HEK-293AAV Stratagene, La Jolla, USA,  
hES cell line I3 Haifa, Israel (Amit et al., 2000) 
iPS cell line iPS-1 Bonn, Germany (Koch et al., 2011) 
iPS cell line MJD Bonn, Germany (Koch et al., 2011) 
Mouse strain C57/BL/6 Charles River, Wilmington, USA 
Mouse strain Fox Scid/Beige (CB17/Icr-Prkdc 
scid/Crl) Charles River, Wilmington, USA 
Mouse strain C57BL/6 Rag2 conditional knock out Taconic, Cologne, Germany 
 
 
Enzyme name Restriction site Manufacturer Registered office 
KpnI 5’…GGTAC^C…3’ 3’…C^CATGG…5’ New England Biolabs Frankfurt, Germany 
NdeI 5’…CA^TATG…3’ 3’…GTAT^AC…5’ New England Biolabs Frankfurt, Germany 
NotI 5’…GC^GGCCGC…3’ 3’…CGCCGG^CG…5’ New England Biolabs Frankfurt, Germany 
PstI 5’…CTGCA^A…3’ 3’…G^ACGTC…5’ New England Biolabs Frankfurt, Germany 
SpeI 5’…A^CTAGT…3’ 3’…TGATC^A…5’ New England Biolabs Frankfurt, Germany 
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2.7  Plasmids 
Plasmid name Portions used Producer 
pAAV-MCS Backbone Stratagene, La Jolla, USA 
pAAV-RC Unaltered for AAV production Stratagene, La Jolla, USA 
pcDNA3.1 Backbone Invitrogen, Karlsruhe, Germany 
pHelper Unaltered for AAV production Stratagene, La Jolla, USA 
pWPXL EF1alpha-eGFP Lausanne, Switzerland (Trono, 2000) 
ZFN18337 Transient expression of upstream ZFN for ATXN3 Sangamo, Richmond, USA 
ZFN18339 Transient expression of downstream ZFN for ATXN3 Sangamo, Richmond, USA 
ZFN18781 Transient expression of upstream ZFN for ATXN3 Sangamo, Richmond, USA 
 
2.8  Bacterial solutions 
 LB agar  
10 g  Tryptone 
5 g  Yeast extract 
5 g  NaCl 
7 g Agar  
H2O was added to 1 l and the mixture was 
autoclaved and stored at 4 °C 
 
 
 LB medium  
10 g  Tryptone 
5 g  Yeast extract 
5 g  NaCl 
1 ml 1 M NaOH 
H2O was added to 1 l and the mixture was 






 SOB medium  
20 g  Tryptone 
5 g  Yeast extract 
0.5 g  NaCl 
0.19 g KCl 
5 ml 2 M MgCl2 
H2O was added to 1 l, pH adjusted to 7.0 with 5 M 
NaOH, then the mixture was autoclaved and 
stored at 4°C 
 
2.9 Cell culture media  
All basal media were ordered from Invitrogen (Karlsruhe). All compounds were mixed and 
sterile-filtered (0.2 μm filter), stored at 4°C and used within 4 weeks. 
 
% MEF (mouse embryonic feeder) 
86 DMEM-high-glucose 
10 FCS 
1 Sodium pyruvate 
1 L-Glutamine 
1 Non-essential amino acids 
1 Pen / Strep 
 
 
% Neural stem cell (N2) medium 
97.5 DMEM/F12 
1 N2 Supplements 
1 Pen/Strep 
0.5 Insulin 
 D-Glucose (1.5 mg/ml) 
 
 
% Neuronal generation (NGMC) medium 
50 Neural stem cell (N2) medium 
48 Neurobasal medium 
2 B27 supplement 




% hPS cell medium 
78 Knockout-DMEM 
18.6 Serum replacement 




 FGF2 (4 ng/ml) 
 
 
% Embryoid body (EB) medium 
78 Knockout-DMEM 
19 Serum replacement 
1 Non-essential amino acids  
1 L-glutamine 
1 Penicillin Streptomycin  
 
 
% Neural stem cell freezing medium 
70 Serum replacement 
20 CytocoonTM Buffer II 
10 DMSO 
 
% FCS-based freezing medium 




2.10   Cell culture solutions 
% 1xTrypsin/EDTA (TE) 
90 PBS 







% Trypsin inhibitor (TI) 
100 PBS 
 Trypsin inhibitor (0.25 mg/ml ≡ 700 units/mg) 
mixed, sterile-filtered and stored at 4°C 
 
 
% Poly-L-ornithine (PO) 
99 H2O  
1 Poly-L-ornithine (1.5 mg/ml stock) 
mixed, sterile-filtered and stored at 4°C 
 
 
% Laminin (Ln) coating solution 
100 H2O 
 Laminin (1 µg/ml) 
 
 
% 0.1% Gelatine 
99.9 H2O 
0.1 Gelatine 
mixed, autoclaved and stored at 4°C 
 
 
% Matrigel (MG) coating solution 
97 H2O 
3 Matrigel (MG) in DMEM:F12 (1:1) 
 
 
 2x HBS buffer 
8 g NaCl 
0.38 g KCl 
0.1 g Na2HPO4 
5 g Hepes 
1 g Glucose 
H2O was added to 500 ml, the pH was adjusted to 
7.05, the mixture was sterile-filtered and stored at -
20°C 
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2.11 Cell culture stock solutions 
Reagent Concentration Solvent 
B27 Used directly from Invitrogen 
EGF 10 µg/ml 0.1 M Acetic acid + 0.1% BSA 
FGF2 10 µg/ml PBS + 0.1% BSA 
G418 50 mg/ml H2O 
Hyg B 100 mg/ml H2O 
Insulin 5 mg/ml 10 mM NaOH 
Laminin Used directly from Sigma 
 
2.12 Molecular biology reagents 
50x Tris-acetate-EDTA-buffer (TAE)  
242 g Tris 
100 ml 0.5 M EDTA (pH 8) 
57.1 ml Water-free acetic acid 
Total volume of 1 l was adjusted with H2O 
For use 50x TAE was diluted with H2O 1:50 
 
 
6x DNA loading buffer  
2 ml 0.5 M EDTA (pH 8) 
6 g Sucrose 
0,2 ml 2% Bromphenol-blue-solution 
0,2 ml 2% Xylene-cyanol-solution 
0,2 g Ficoll 
3,8 ml Aqua bidest. 
The solution was mixed well, prepared in 1 ml 
aliquots and stored at 4°C 
 
 
 PFA fixation solution (4%) 
40 g PFA 
1000 ml H2O 
The solution was heated until PFA dissolved 
completely, pH adjusted to 7.4 and sterile filtered. 
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% Immuno-blocking solution 
89.9 PBS 
10 FCS 
0.1 Triton X100 (only for intracellular epitopes) 
 
 
 Moviol / DABCO 
12 ml Tris solution (0.2 M; pH 8.5) 
6 ml H2O 
6 g Glycerol 
2.6 g Moviol 
0.1 g DABCO 
 
 
 SDS-PAGE resolving gel buffer 




 SDS-PAGE stacking gel buffer 




 SDS-PAGE running buffer 
3 g Tris 
14.4 g Glycin 
1 g SDS 










 Western blotting buffer 
3 g Tris 
14.4 g Glycin 
add H2O to 800 ml (pH 8.8) 
Add 200 ml Methanol prior to use. 
   
 
10x TBST 
121 g Tris 
87 g NaCl 
10 ml Tween-20 
add H2O to 1000 ml 
 
 
% Protein loading buffer 
75.75 Tris solution (0.1 M; pH 6.8) 
20 Glycerol 
4 SDS 
0.25 Bromphenol blue 
 
 
 Southern denaturing buffer 
20 g NaOH 
87.66 g NaCl 
add H2O to 1000 ml 
Adjust pH to 7.0 
 
 
 Southern neutralizing buffer 
60.56 g Tris-HCl 
87.66 g NaCl 
add H2O to 800 ml 
Adjust pH to 7.0 with concentrated HCl, then add 
H2O to 1000 ml. 
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20x SSC Transfer Buffer 
175.5 g NaCl 
88.2 g Na citrate 
add H2O to 800 ml 
Adjust pH to 7.0 with concentrated HCl, then add 
H2O to 1000 ml. 
 
 
 Southern washing buffer 
11.6 g Maleic acid 
8.77 g NaCl 
300 µl Tween-20 
add H2O to 1000 ml 
Adjust pH to 7.5 with solid NaOH. 
 
 
 Maleic acid buffer 
11.6 g Maleic acid 
8.77 g NaCl 
add H2O to 1000 ml 
Adjust pH to 7.5 with solid NaOH. 
 
 
 Southern detection buffer 
15.76 g Tris-HCl 
5.84 g NaCl 
add H2O to 1000 ml 




1.58 g Tris-HCl 
0.29 g EDTA 
add H2O to 1000 ml 





Name Application Producer 
ApE – A plasmid Editor 
v2.0.7 Cloning strategies M. Wayne Davis 
AxioVision 4.5 Fluorescence microscopy Carl Zeiss  MicroImaging 
Chromas v2.31 DNA sequence analysis Technelysium 
ClustalW v1.83 Sequence alignment EMBL-EBI (Thompson et al., 1994) 
Illumina BeadStudio SNP analysis Illumina 
Microsoft Office 2008 Figures and text processing Microsoft 
Primer3 v0.4.0 Primer picking Rozen and Skaletsky (2000) 
Quantity One Electrophoresis gel documentation Bio-Rad 
RepeatMasker Gene locus analysis 
Arian Smit, Gustavo 
Glusman, Robert 
Hubley 





Name  Producer Office 
DIG High Prime DNA Labeling and 
Detection Starter Kit II Roche Applied Science Basel, Switzerland 
DNeasy Blood Tissue Kit Qiagen Hilden, Germany 
iScript cDNA Synthesis Kit Bio-Rad München, Germany 
MEGAscript T7 Kit Ambion Austin, USA 
PCR DIG Probe Synthesis Kit Roche Aplied Science Basel, Switzerland 
peqGOLD CyclePure Kit Peqlab Biotechnologie Erlangen, Germany 
peqGOLD Gel Extraction Kit Peqlab Biotechnologie Erlangen, Germany 
peqGOLD 
Plasmid Miniprep Kit I Peqlab Biotechnologie Erlangen, Germany 
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Name  Producer Office 
PureYield 
Plasmid Maxiprep System Promega Mannheim, Germany 
QuikChange Lightning Site-Directed 
Mutagenesis Kit Stratagene 
Waldbronn, 
Germany 
RNeasy Kit Qiagen Hilden, Germany 
ScriptCap  m7G Capping System CellScript Madison, USA 
 
2.15 Primer 
Name Primer sequence (5’-3’) 
P1 upstream HA fw GGGTTCCTGC^GGCCGCCGTTTCTGCTTTTTAAAGCTCATGT                           NotI 
P2 upstream HA rv TATGGATCCA^CTAGTTATGTAAATACAAACACAGAAAACCAA                           SpeI. 
P3 downstream HA fw 
ACCACTGTGCA^TATGGGTTATTTTGTGATGAAAATACCTACC 
                          NdeI. 
P4 downstream HA rv 
GGGTTCCTGC^GGCCGCCTACTACTAATTGGCCAAAGTTTAA
GA 
                           NotI. 
P5 Sca3 fw AGCACTTCCATATTTTAAAGTAATCTG 
P6 Sca3 rv TGCTCCTTAATCCAGGGAAA 
P7 ADK fw TTGCAGATGATTTTGCACCT 
P8 ADK rv GACCCCTTTGGGGTATCTGT 
P9 Neo fw GCTTGGGTGGAGAGGCTATT 
P10 Neo rv GCGATACCGTAAAGCACGAG 
P11 QuikChange fw GCAGCAGGGGGACCTGTCAGGACAGAGTT 
P12 QuikChange rv AACTCTGTCCTGACAGGTCCCCCTGCTGC 
 
In case of cloning primers, restriction sites in the overhanging ends are indicated in red, while 





Primary antibody Dilution Source 
Actin 1:2000 Sigma Aldrich, Deisenhofen, Germany 
ADK 1:500 Abcam, Cambridge, United Kingdom 
Ataxin-3 1:100 ProteinTech, Chicago, USA 
DACH1 1:50 ProteinTech, Chicago, USA 
EGFP (rb) 1:3000 Abcam, Cambridge, United Kingdom 
GABA 1:500 Sigma Aldrich, Deisenhofen, Germany 
GFAP 1:1000 DAKO, Glostrup, Danemark 
Map2ab 1:500 Chemicon, Temecula, USA 
Nestin 1:500 R&D Systems, Minneapolis, USA 
NeuN 1:100 Millipore, Billerica, USA 
Neurofilament (HO14) 1:100 gift from Virginia Lee, Philadelphia, USA 
 
 
Secondary antibody Dilution Source 
Cy3 gt-anti-ms 1:1000 Jackson , West Grove, USA 
Cy3-gt-anti-rb 1:1000 Jackson , West Grove, USA 
Cy3-dk-anti-gt 1:1000 Jackson , West Grove, USA 
Cy3-gt-anti-rat 1:1000 Jackson , West Grove, USA 
FITC-gt-anti-ms 1:1000 Jackson , West Grove, USA 
FITC-gt-anti-rb 1:1000 Jackson , West Grove, USA 
HRP-gt-anti-ms 1:10000 Thermo Scientific, Waltham, USA 
HRP-gt-anti-rb 1:10000 Thermo Scientific, Waltham, USA 
 




3 Methods  
3.1 In vitro differentiation of hPS cells into lt-NES cells  
All cell culture experiments were performed in a sterile laminar flow hood using sterile media, 
glass and plastic instruments. Cells were cultivated in an incubator at 37°C, 5% CO2 and 
saturated air humidity. In vitro differentiation of hPS cells (hES and iPS cells) into long term 
proliferating pluripotent stem cell-derived neuroepithelial stem (lt-NES) cells was performed 
as described previously (Koch et al., 2009).  
HPS cells were cultivated on a layer of irradiated mouse fibroblasts and grown in hPS cell 
medium. Medium was changed daily and passaging was performed using collagenase IV (1 
mg/ml). To induce differentiation, embryoid bodies (EBs) were generated by cultivating hPS 
cell colonies in EB medium as floating aggregates. After four days, EBs were transferred to 
poly-l-ornithine (PO) coated tissue culture dishes and propagated in N2 (Invitrogen) medium 
containing FGF2 (10 ng/ml; R&D Systems). Neural tube-like structures developed within 10 
days in the EB outgrowth and were mechanically isolated and propagated as free-floating 
neurospheres in N2 medium containing FGF2 (10 ng/ml). After three days, neurospheres 
were incubated with trypsin/EDTA (TE; Invitrogen) and trypsin inhibitor (TI; Invitrogen), 
mechanically triturated into single cells and plated on poly-l-ornithine/laminin (PO/Ln; both 
Sigma Aldrich) coated plastic dishes. Obtained lt-NES cell lines were cultivated in N2 
medium containing FGF2, EGF (both 10 ng/ml; R&D Systems) and 1 µl/ml B27 supplement 
(Invitrogen) on PO/Ln cell culture dishes and passaged using TE/TI. Seeding densities were 
5 - 8 x105 cells/cm2. Lt-NES cell lines can be passaged up to >100 passages and were 
monitored daily regarding proliferation ability and morphological integrity. For storage, 
trypsinized lt-NES cells were resuspended in neural stem cell freezing medium and directly 
transferred to −80°C or liquid nitrogen storage tanks. 
For the generation of an adenosine kinase knock out cell line, lt-NES cells derived from the 
parental human embryonic stem cell line I3 were used, while gene correction of the ATXN3 
gene locus was performed in MJD-lt-NES cells gained from patient-derived induced 
pluripotent stem (iPS) cells. 
 
3.2 Differentiation of lt-NES cells into neuronal and astrocytic cultures 
Lt-NES cells represent a standardized multipotent stem cell population that constantly retains 
its capability to generate defined cultures of neurons and glial cells over long-term culture. To 
initiate terminal differentiation, lt-NES cells were transferred to matrigel (MG)-coated cell 
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culture dishes. Upon reaching confluence, culture medium was changed to NGMC medium, 
which was exchanged every second day. To generate astrocytes-enriched cultures, 10% 
FCS was added to culture media, while neuronal enrichment was achieved by adding 10 µM 
DAPT (Sigma) for the first 5 days of differentiation. 
 
3.3 Immunocytochemical analysis 
Cells were fixed in 4% PFA for 5 min at room temperature, washed twice with PBS and 
blocked with 10% FCS and 0.1% Triton-X-100 in PBS for 30 min at room temperature. The 
respective primary antibodies (listed) were applied overnight at 4°C in blocking solution. Cells 
were washed twice with PBS before secondary antibodies (listed) were applied for 2 h at 
room temperature. Cell nuclei were counterstained with DAPI and finally cells were rinsed 
with PBS, mounted with Moviol and covered with a glass coverslip. 
 
3.4 SNP analysis and sequencing 
Genomic DNA was prepared using the DNeasy Blood & Tissue Kit (Qiagen). Whole genome 
single nucleotide polymorphism (SNP) genotyping was performed at the Institute of Human 
Genetics at the University of Bonn. Genomic DNA at a concentration of 50 ng/μl was used for 
whole genome amplification. Afterwards, the amplified DNA was fragmented and hybridized 
to sequence-specific oligomers bound to beads on an Illumina Human 660W Quad chip. 
Data was analyzed using Illumina BeadStudio. 
 
3.5 Western immunoblotting 
Cells were scraped from the dishes and incubated in RIPA buffer (1 hr; 4°C; Sigma Aldrich) 
containing protease inhibitors (Roche cOmplete ULTRA). Lysates were clarified by 
centrifugation (16000 rcf; 15 min; 4°C) and run on a SDS-PAGE using standard gels. Briefly, 
10% SDS-PAGE gels contained resolving and stacking gels and were cast using 30% 
Acrylamid/Bisacrylamid (37.5:1; Carl Roth), TEMED, 10% APS, and the respective gel 
buffers. Protein lysates were loaded on SDS-PAGE gels and run in MINI-Protean chambers 
(Biorad). Seperated proteins were blotted on MeOH-activated PVDF membranes, blocked 
with 10% Roti-Block (Carl Roth) in TBST for 20 min and incubated with an appropriate 
primary antibody (listed) over-night at 4°C. Washed membranes were incubated with an 
HRP-linked secondary antibody (1 h) and visualized by chemoluminescence (Thermo 
Scientific SuperSignal West Chemiluminescent Substrates).  
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3.6 Design of AAV virus for the targeting of ATXN3 gene in human lt-NES 
cells 
The general composition of an AAV targeting vector is illustrated in Fig. 3.1. Two homology 
arms (HAs) flanking the selection cassette are necessary for site-specific targeting and were 
amplified from genomic DNA of the same cell line that was later targeted. For primer design 
and in-silico genome analysis, the Ensembl databases (http://www.ensembl.org) and Primer3 
(http://frodo.wi.mit.edu/) were used. For selection, a promoterless cassette bearing neomycin 
resistance was chosen and cloned into the commercially pAAV-MCS vector (Stratagene). 
 
3.6.1 Generation of homology arms  
The ATXN3 gene consists of 12 exons, of which exon 10 contains the polyglutamine 
encoding CAG repeat motif. Based on an in silico analysis with RepeatMasker, exon 10 and 
the surrounding intronic sequences did not contain any repetitive motifs beside the CAG 
repeat and thus was found to be suitable for our targeting strategy. The AAV vector system 
allows the incorporation of around 2 kb for HA usage, which should be evenly distributed 
between the two HAs lying upstream and downstream of the selection cassette. With a size 
of 405 bp, Exon 10 of the ATXN3 gene is small enough for the complete incorporation into 
the downstream HA. Primers were picked using the Primer3 algorithm (Rozen and Skaletsky, 
2000) on the intronic sequences surrounding the exon, generating a downstream HA of 1165 
bp length (Fig. 3.1). The upstream HA was chosen to contain only intronic sequences found 
between exons 9 and 10 with a length of 814 bp. 
For the amplification of the two homology arms, genomic DNA was isolated from MJD-lt-NES 
cells using the Qiagen DNeasy Blood and Tissue DNA isolation kit according to the 
manufacturer’s instructions. The homology arms were amplified from genomic DNA by PCR 
using primers with overhanging ends containing restriction sites for NotI, SpeI or NdeI (Tab. 
2.14). Primer sequences encompassed 26-27 nucleotides of target binding, the restriction 
enzyme recognition site and additional nucleotides homologous to the selection cassettes 
resulting in an overall-length of 41-43 nucleotides.  
2 µM of each forward and reverse primers, 0.025 U/µl Taq-Polymerase, 2 mM of Mg2+ and 
0.2 mM dNTPS were added to 1 µg of DNA in a total volume of 50 µl PCR buffer. The cycling 
conditions were the following: 1 cycle of  94°C for 5 min; 20 cycles of 94°C for 30 s, 53°C for 
30 s and 72°C for 90 s; 1 cycle of 72°C for 10 min. The primers were removed using the 
peqLab PCR cycle pure kit. The extracted DNA was digested with NotI (20 units) and SpeI 
(10 units) in 20 µl NEB buffer 2 or with NotI (10 units) and NdeI (15 units) in 20 µl NEB buffer 
3 for 90 min at 37°C. Electrophoresis on a 0.8% agarose gel yielded strong bands of correct 
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sizes, in case of the downstream HA products of both alleles were gained, of which the 
shorter variant was excised and gel-extracted using the peqLab gel extraction kit. 
 
3.6.2 Cloning of targeting vector 
The contents of the targeting vector are depicted in Fig. 3.1. Besides a classical backbone 
with Amp resistance for bacterial amplification it contains the targeting cassette flanked on 
both sides by the ITRs that give rise to the hairpin shaped termini of the viral genome. 
Between the ITRs the homology arms are situated and in between them, lays the selection 
cassette containing a synthetic exon promoter trap (SEPT) (Topaloglu et al., 2005) that 
allows neomycin resistance only if integrated into an actively transcribed gene locus, thus 
massively increasing the amount of positive resistant clones. The ITRs and the backbone are 
derived from the pAAV-MCS vector, which is part of the commercial helper-free AAV-system 
from Stratagene. 
The creation of the targeting vector is a multi-step-process: first the upstream HA was ligated 
into a pWpXL-backbone containing the SEPT cassette, then this larger fragment was excised 
and, together with the downstream HA, ligated into the pAAV-MCS backbone. The excision 
and ligation process is shown in Fig. 3.1. 
The pWpXL vector contained the whole SEPT cassette directly downstream of its multiple 
cloning site, bearing restriction sites for NotI and SpeI. To open the plasmid and insert the 
upstream HA in front of the SEPT cassette, both were digested with NotI (20 units) and SpeI 
(10 units) in 20 µl NEB buffer 2 for 90 min at 37°C, and purified from a 0.8 % agarose gel 
using the peqLab gel extraction kit according to the manufacturer’s instructions. The 
linearized backbone (50 ng) was then combined with the digested homology arm (150 ng) so 
that the insert was in 20 fold molar excess of backbone. Ligation was performed using T4 
ligase (400 units) in 20 µl NEB T4 ligation buffer for 30 min at 22°C. The ligated vector was 
transformed into competent E. coli cells. 100 µl of frozen competent bacteria were thawed on 
ice, all 20 µl of the DNA solution were added, and the reaction tube chilled on ice for 30 min. 
Then, heat shock was performed for 90 sec at 42°C and the sample again chilled for 5 min. 
To allow the cells to gain antibiotic resistance, 500 µl SOB medium was added and the tube 
shaken in an incubator at 37°C for 90 min. Cells were then plated on LB agar plates 
containing 100 mg/l ampicillin and incubated over night (o/n) at 37°C. 
The next morning, plates were put into the fridge to pick colonies in the evening. Each colony 
was grown o/n at 37°C on a shaker in 3 ml LB medium containing ampicillin. The DNA was 
isolated using the peqLab DNA mini prep kit according to the manufacturer’s instructions. 1 µl 
of the preparations were further analyzed by electrophoresis on a 1 % agarose gel after 
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digestion with NotI (10 units) and NdeI (15 units) in 20 µl NEB buffer 3 for 90 min at 37°C. 
Clones showing two bands (backbone and fusion of upper HA with selection cassette) of the 
correct sizes were considered positive. One of these clones was selected and grown o/n in 
shaking incubator at 37°C in 200 ml LB medium containing 100 mg/l ampicillin. DNA 
purification was performed using the Promega PureYield Plasmid Maxiprep System kit 
according to the manufacturer’s instructions. 
The next ligation step combined to downstream HA with adjacent SEPT cassette with the 
PCR-amplified upstream HA into the pAAV-MCS backbone to gain the functional targeting 
vector. The pAAV-MCS plasmid was digested with 10 units of NotI in 20 µl of NEB buffer 3 
for 90 min. at 37°C and the larger fragment (2887 bp) was purified from a 0.8 % agarose gel 
using the PeqLab gel extraction kit. To prevent unwanted circularization, the linearized 
fragment was dephosphorylated using 10 units of alkaline phosphatase in 10 µl of 
dephosphorylation buffer. After an incubation of 30 min. at 37°C the alkaline phosphatase 
was inactivated for 15 min. at 65°C. The downstream HA–PCR product and the fusion-
construct of upstream HA with selection cassette was digested with NotI and NdeI as 
described above. Ligation was performed with 50 ng of pAAV-MCS-backbone, 350 ng of 
downstream HA and 50 ng of upper-HA-selection cassette-fusion-construct in 20 µl NEB T4 
ligation buffer with 400 units of T4 ligase for 30 min at 22°C. This time, the HA was used in 
200 fold excess of the other segments to ensure efficient incorporation. Transformation of 
competent cells and clone picking were performed as described above. Positive clones were 
chosen on the results of digestions with either NotI or SpeI or the combination of both (each 
10 units in 20 µl NEB buffer 3) following agarose gel electrophoresis. Again, PCR was 
conducted to verify integration of the homology arms. 
 
3.6.3 Mutation of targeting vector 
To easily discriminate between the original wild type allele and the gene-corrected allele, a 1-
bp-mutation was inserted in the targeting vector. This mutation is a silent one, which would 
not affect the translated protein. For modification of the plasmid, the QuikChange Lightning 
Site-Directed Mutagenesis Kit (Stratagene) was used following the manufacturers’ 





Figure 3.1: Cloning strategy for ATXN3-AAV targeting vector for site-specific integration. 
Upstream and downstream homology arms (HAs) were PCR-amplified from the shorter allele of exon 
10 of the ATXN3 gene of MJD-patient derived lt-NES cells. Primers used also carried restriction 
nuclease recognition sequences for cloning purposes. The upstream HA was first ligated directly in 
front of the SEPT cassette, which was already present in a pWPXL vector, using its multiple cloning 
site (MCS). The new construct was expanded and used to excise an upstream HA+ SEPT fragment 
for the next ligation step. Together with the downstream HA; it was ligated in a dephosphorylated 
pAAV-MCS backbone to gain the complete targeting vector composed of a SEPT cassette flanked by 
homology arms for site directed integration, nested between inverted tandem repeat (ITR) sequences 
of the viral backbone. 
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3.7 Preparation of competent E. coli and glycerol stocks  
Competent cells were prepared and transformed according to the Inoue method for ultra 
competent cells (Inoue et al., 1990). Of every plasmid-producing clone, glycerol stocks were 
prepared allowing an easy and quick access to the desired DNA. From the culture flask used 
for maxi preparation of its plasmid DNA, 800 µl of bacterial solution were thoroughly mixed 
with 200 µl of glycerol, transferred into a cryovial and frozen at -80°C. The bacterial cells can 
be stored like this for at least one year. To raise a new culture from the stock, a small amount 
of frozen cells was scratched with a pipette tip and dripped into fresh LB medium with 
ampicillin. The stock did not have to be thawed for this purpose. 
 
3.8 Generation of AAV particles 
The HEK-293 cell line is of human embryonic kidney origin and has been transformed by the 
adenoviral E1A gene product. Hence it already brings along one of the needed components 
to produce adenoviral-associated viruses. The missing parts of the adenoviral genome are 
brought into the cells by helper plasmids, so that the targeting vector can be used for 
structural design of the AAV genome. Transient transfection into HEK-293 cells is a common 
way to produce and harvest both proteins and viral particles. These cells are known to be 
highly transfectable by the calcium phosphate method and are used to produce large 
amounts of AAV particles after triple transfection of the three viral plasmids. 
AAV-293 cells (Stratagene) that are further optimized for AAV particle generation were used. 
Cells were propagated as monolayer culture until confluency reached 80% and then 
passaged with TE. 
 
3.8.1 Triple transfection using the calcium phosphate method  
To initiate viral particle production, AAV-293 cells were transfected with the three plasmids 
pAAV-RC, pHelper (both from Stratagene) and the targeting vector. 
AAV-293 cells were grown on 15 cm gelatine coated dishes until a confluence of 90% was 
reached. 30 min prior to transfection, medium was changed to fresh MEF containing 25 µM 
chloroquine which helps stabilizing DNA for better uptake. The targeting vector (15 µg) was 
mixed with pAAV-RC and pHelper plasmids (10 µg each) in 700 µl of water. This solution 
was well mixed with 89 µl of 2.5 M CaCl2. In a 15 ml Falcon tube, 700 µl of 2xHBS were 
prepared. A 2 ml plastic pipette was put into this falcon while the DNA-solution was taken 
with a 1 ml micropipette to be dropped carefully onto the outside of the plastic pipette while a 
pipette boy was used to blow air into the 2xHBS. The DNA-solution now floated into the 
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2xHBS and was thoroughly mixed by ascending bubbles. This transfection reagent was 
incubated for 30 min. at room temperature and then added dropwise to the cell dish. After 6 
h, the medium was replaced. 
 
3.8.2 Harvesting and freezing of AAV particles 
48 h after transfection, cells were detached from the dish with a cell scraper, pelleted and 
washed with PBS. The cells of one 15 cm dish were resuspended in 1 ml of PBS and 
subjected to five cycles of freezing and thawing and finally centrifuged for 3 min at 12 000 g 
to remove cell debris. The supernatant was frozen at -80°C and could be directly used for 
treatment of target cells. 
 
3.9 Gene targeting of MJD-lt-NES cells 
Compared to lentiviral vectors, the transduction efficiency of AAV particles is relatively low. 
As the aim was to generate monoclonal cell lines, this low efficiency was an advantage that 
allowed single clones to grow at distances, which prevented any unwanted mixing.  
 
3.9.1 Transduction of AAV particles 
For viral transduction, MJD-lt-NES cells were seeded on 12-well-plates and infected with 50 
µl of viral stock-solution per well. After 24 h at 37 °C, the media was aspirated from the cells 
and substituted by fresh medium. After three days of propagation, cells were split onto 6 well-
plates and from the following day on taken under antibiotic selection with G418 (100 µg/ml.) 
Within one week of selection, all non-targeted cells were dying. 
As resistant colonies emerged, selection was removed to not further stress the cells and to 
let the existing colonies grow. As soon as colonies began to form spherical bulges, they were 
picked with a 10 µl micropipette by scratching and soaking, and then plated onto 48 well-
plates. The clones were again taken under selection and expanded. Whenever enough cells 
were available to form a monolayer on a 12-well, they were dissociated with trypsin and 
separated. As soon as enough cells of a clone were present to secure the propagation, 
genomic DNA was isolated for screening purposes. 
 
3.9.2 Screening for targeting events  
Exchange of the expanded allele against its wildtype variant should be easily detected in a 
PCR screen for exon 10 of ATXN3. Therefore, genomic DNA was extracted using the 
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DNeasy Blood & Tissue Kit (Qiagen). PCR amplification of Exon 10 of the ATXN3 gene was 
performed using Phusion Polymerase (Finnzymes) with primers P4 and P5 (Table 2.4). PCR 
included a preincubation at 98 °C for 30 s followed by 35 cycles of denaturation at 98°C for 
10 s, annealing at 60°C for 30 s and extension at 72°C for 60 s with a final extension step at 
72°C for 10 min. Fragments were extracted from the gel and subsequently sequenced. 
Sequencing was performed by Seqlab Laboratories. Positive clones and controls were 
further expanded and used for analysis of ataxin-3 by SDS-PAGE and Western Blotting. 
 
3.9.3 Cre-mediated excision of selection cassette 
After the selection process, the SEPT cassette had to be removed to again derive a 
functional expression of ataxin-3 protein from the targeted allele. The incorporated loxP 
sequences at both ends of the cassette allowed its excision with Cre protein. To transiently 
express Cre in the targeted MJD-lt-NES cells, transfection of mRNA coding for Cre protein 
was chosen. 
RNA was synthesized with the MEGAscript T7 kit (Ambion), with 0.5 μg of Cre sequence 
containing plasmid to template a 40 μL reaction. The T7 capping system ScriptCap (Ambion) 
with a ribonucleoside mix of adenosine triphosphate (2 mM), guanosine triphosphate (2 mM), 
cytidine triphosphate (1.5 mM), uridine triphosphate (1.5 mM), 5-methylcytidine triphosphate 
(375 µM) and pseudouridine triphosphate (375 µM, all from Ambion) was used. Reactions 
were incubated 4 hr at 37°C and DNAse treated. RNA was purified with Quick Spin RNA 
columns (Roche), followed by treatment with antarctic phosphatase (New England Biolabs) 
for 20 min at 37°C to remove residual 5′-triphosphates. The resulting modified RNA was 
repurified, quantitated by Nanodrop (Thermo Scientific), and adjusted to 100 ng/μL working 
concentration by addition of H2O. 
RNA transfections were performed with RNAiMAX (Invitrogen) cationic lipid delivery vehicles. 
RNA and reagent were first diluted in Opti-MEM basal media (Invitrogen). 100 ng/μL RNA 
was diluted 5× and 5 μL of RNAiMAX per microgram of RNA was diluted 10×, then these 
components were pooled and incubated 15 min at room temperature (RT) before being 
added dropwise to culture media. RNA transfections were performed in Opti-MEM plus 2% 
FBS. After 6 hrs, media was replaced by fresh N2. After 2 days, another RNA transfection 
was applied and the cells analyzed for successful excision of selection cassette via PCR and 
western blot analysis. 
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3.10 Southern blot analysis 
10 µg of genomic DNA isolated with DNeasy Blood & Tissue Kit (Qiagen) was digested with 
3 units of PstI restriction enzyme per µg DNA at 37°C over night in a total volume of 400 µl. 
Digested DNA was loaded onto 0.8% agarose gel and electrophoresed at 40 volts, 35 mA for 
8 hours. 
Blotting on Nytran SuPerCharge® Nylon membranes (Whatman) was performed using a 
TurboBlotter system (Whatman). Agarose gel was denatured for 30 min at room temperature 
in denaturing buffer, afterwards rinsed in distilled water and transferred to neutralizing buffer. 
After 30 min of slow shaking, gel was soaked in 20x SSC transfer buffer for 30 min. Nylon 
membrane was wetted in distilled water and then soaked in 20x SSC transfer buffer for 5 
min. TurboBlotter was put together following manufacturer’s instructions. The nylon 
membrane was placed on the blotting paper stack followed by the agerose gel and additional 
sheets of blotting paper. Transfer was carried out overnight with 20x SSC transfer buffer. 
Following transfer, the transfer membrane was washed in 2x SSC for 5 min and dried with 
blotting paper. Immobilization of DNA onto the membrane was done by baking the 
membrane for 2 hrs at 80°C. 
For the generation of southern probes, PCR DIG Probe Synthesis Kit (Roche) was used 
according to the manufacturer’s instructions with a PCR template cycled from the neomycin 
resistance gene within the SEPT cassette with primers P9 and P10. Hybridization and 
detection of southern blots was carried out with the DIG High Prime DNA Labeling and 
Detection Starter Kit II (Roche). Southern blot membranes were hybridized with 30 ng/ml of 
denatured DIG-labeled DNA probe in 10 ml of DIG Easy Hub solution, sealed in plastic foil, 
over night at 40°C. The next day, membranes were washed twice for 5 min in ample 2 x 
SSC, 0.1% SDS at room temperature followed by two washing steps in 0.5 x SSC, 0.1% SDS 
at 68°C. Immunological detection was performed according to guidelines from the DIG High 
Prime Kit in a Chemidoc imaging system (Bio-Rad). 
 
3.11 Transcript analysis of gene corrected MJD-lt-NES cells 
To verify the functional transcription from both alleles, wildtype and gene-corrected, ATXN3 
mRNAs were sequenced and checked for the integrated 1-bp-mutation. Total RNA from cells 
was purified (Quiagen RNeasy kit) and reversely transcribed into cDNAs (Biorad iScript 
cDNA synthesis kit). PCR was performed using standard protocols (Invitrogen Taq DNA 
Polymerase) with primers P5 and P6. 
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3.12 Glutamate treatment and microaggregate formation analysis 
Stimulation experiments were conducted in neuronal cultures 6-8 weeks after growth factor 
withdrawal. MJD-neurons or Ctrl-neurons cultured in 3,5 cm dishes were washed 3 times 
with 2 ml BSS (balanced salt solution) containing 25 mM Tris, 120 mM NaCl, 15 mM glucose, 
5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, pH 7.4. After treatment with 100 µM L-glutamate 
(Sigma G8415) in BSS for 30 min cells were washed again 3 times and either immediately 
frozen in liquid N2 followed by lysis in RIPA-buffer (50 mM Tris, 150 mM NaCl, 0.2 % Triton 
X100) containing 25 mM EDTA or left to recover for 30 min in differentiation media followed 
by a second 30 min L-glutamate treatment in BSS, and subsequently cultured in 
differentiation media until analyzed 24 h later. 
For analysis of fragmentation and aggregation of ataxin-3 by SDS-PAGE and Western 
Blotting, extracts were analyzed either immediately after lysis or after fractionation. For 
fractionation, lysates were centrifuged at 22,000 x g for 20 min at 4°C. The pellet fractions 
were separated from supernatants (Triton-X 100-soluble fraction) and homogenized in RIPA 
buffer containing 2% SDS followed by a second centrifugation step. The supernatants (SDS-
soluble fraction) were removed, and the remaining pellets were incubated for 16 h in 100 % 
formic acid at 37°C (Haacke et al., 2007; Hazeki et al., 2000). After evaporation in a Speed 
Vac concentrator (Thermo Scientific), the pellet was dissolved in Laemmli-buffer (SDS-
insoluble fraction) followed by pH-adjustment with 2 M Tris-base for SDS-PAGE analysis. 
3.13 Transfection of Zinc-Finger-Nucleases and clone selection 
For the delivery of Zinc finger nucleases (ZFN) into cell nuclei, coding plasmids for its 
transient expression were nucleofected into lt-NES cells. Three different plasmids bearing 
ZFNs developed by Sangamo were used, ZFN18339 coding for downstream binding, 
ZFN18337 and ZFN18781 coding for upstream binding of target sequence. Pairs of either -
39 and -37 or -39 and -81 were used to target the adenosine kinase while the combination of 
-37 and -81 served as control. 
For nucleofection, the Nucleofector system (Lonza) was used with Solution V and program 
B23. Each reaction used 1 µg of each ZFN plasmid, making a total of 2 µg of DNA. 1 x 10^6 
lt-NES cells were pelleted and resuspended in 100 µl of supplemented Nucleofector Solution 
V and immediately mixed with the DNA into a nucleofection cuvette. The suspension was 
nucleofected with program B23 and directly plated into one well of a sixwell plate already 
covered with N2F media. After 6 hrs, media was exchanged. 
Being an enzyme, the disruption of adenosine kinase could be selected for with two chemical 
compounds that are metabolized by ADK into toxic species. Two passages after 
nucleofection, chemoselection of cells started with 10 µM 8-Cl-cAMP (8-Chloroadenosine 
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3’,5’-cyclic monophosphate; Enzo) and 10 µM 8-Cl-Ado (8-Chloroadenosine; Enzo). After 20 
days of selection, resistant colonies emerged which where further expanded and analyzed 
via sequencing of the ZFN recognition site with primers P7 and P8. 
 
3.14 Measurements of adenosine levels in cell culture supernatants 
To decipher to what extent the disruption of adenosine kinase leads to a higher level of 
adenosine secretion by cells in culture, adenosine levels were measured using high-pressure 
liquid chromatography (HPLC). These analyses were performed by the group of Christa E. 
Müller at the Department of Pharmacy at the University of Bonn. 
Normal cell culture media could not be used with the detection method, and therefore a cell 
buffer with reduced organic compounds was used (140 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 
2.2 mM MgSO4, 0.48 mM NaH2PO4, 2 mM Na-Pyruvate, 5.5 mM D(+)-Glucose, 10 mM 
HEPES, pH 7.4) To prevent adenosine breakdown, addition of 100 µM of the deaminase-
inhibitor EHNA (erythro-9-2-hydroxy-3-nonyl-adenine, Sigma) was necessary. Supernatants 
of lt-NES cells, neuronal- or astrocytic-enriched cultures were collected at distinct time points 
after switch to cell buffer and lyophilized. The resulting pellets were dissolved in 
methanol/acidic acid using sonification. After precipitation of inorganic salts by centrifugation 
for 1 h at 10,000 g, supernatants were directly used for mass spectrometric analysis. 
Samples were injected into a HPLC Dionex Ultimate 3000 system (Thermo Scientific) 
coupled to a micrOTOF-Q mass spectrometer (Bruker) with an electrospray ionization 
source. Chromatographic separation was performed on a hydrophobic ether-bonded phenyl-
phase column. It was started with 100% H2O containing 0.1% acetic acid followed by a 
gradient to 100% acetonitrile containing 0.1% acetic acid. Positive scan MS was observed 
from 50-1000 m/z optimized to peak 268.1038. For quantifying the extract ion counts 
268.1038 ± 0.01 was used. Calibration curves were determined by dissolution of a broad 
range of adenosine concentrations in acetonitrile : water (1:1), and the cell buffer used. The 
limit of detection of the method was below 1 ng/ml for adenosine dissolved in the acetonitrile-
water mixture while in cell bufferthe detection limit was about 10-fold higher. 
 
3.15 Mouse experiments 
In pilot experiments, mouse strains C57Bl/6 and SCID/beige were used. For all cell 
transplantation experiments, immunodeficient Rag2 constitutive knock out mice with C57Bl/6 
background (Taconic) were used. All animals were treated according to guidelines approved 
by the European Ethics Committee (decree 86/609/EEC). The animals were kept under 
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environmentally controlled conditions (12 h normal light/dark cycles, 20–23°C and 50% 
relative humidity) with food and water ad libitum.  
 
3.15.1  Stereotactic transplantation into the mouse brain 
Cell transplantation into the mouse brain was performed by standard procedures of the 
Institute of Reconstructive Neurobiology. Cells for transplantation were trypsinized and re-
suspended in CytoconTMBuffer II containing 0.1% DNAse (200.000 cells/µl). Mice were 
anesthetized with Fentanyl (0.05 mg/kg BW i.p.), Midazolam (5 mg/kg BW i.p.), Meditomidin 
(0.5 mg/kg BW i.p.) and heads were shaved and sterilized. Mice were positioned in a 
stereotactic apparatus and the skull was opened sufficiently to reveal the lambda and 
bregma points. The injection needle was positioned to target the desired coordinates. Fascia 
and pericranium were removed with forceps. A burr hole (0.5 – 1.0 mm) was drilled through 
the skull using a sterile bone drill. The injection needle containing cell suspension was 
lowered slowly (~1 mm/5 sec) down to the target depth, and the cell suspension was injected 
slowly (~1 µl/min). Following injection, the needle was slowly withdrawn and bone wax was 
applied to seal the hole in the skull. Skin was closed with wound clips and mice were 
transferred to a warming pad for standard post-operative care. Mice were given Naloxon (0,4 
mg/kg BW s.c.), Flumazenil (0.5 mg/kg BW s.c.) and Atipamezol (5 mg/kg BW s.c.) to stop 
anesthesia and Carprofen (50 mg/kg BW s.c.) against pain. Following operation, mice were 
routinely checked for health and behavior. 
 
3.15.2 Generation of epileptic animals by injection of pilocarpine 
For evaluation of this epilepsy model C57/Bl6 mice were chosen. To limit peripheral 
parasympathetic effects like the excessive dehydration, methylscopalamine (Sigma) was 
applied (1mg/kg body weight). Mice of 60 days age and body weight over 20 g received a 
pilocarpine (Sigma) dosage of 340 mg/kg body weight s.c. Pilocarpine was administered 
stepwise until status epilepticus was reached. Mice were observed for signs of seizures 
according to the following acute stages of Racine’s classification (Racine, 1972): Stage 1: 
Immobility, eye closure, twitching of vibrissae, facial clonus. Stage 2: Head nodding, 
chewing, severe facial clonus, wet dog shakes, repetitive movements. Stage 3: Clonus of 
one forelimb. Stage 4: Rearing, bilateral forelimb clonus. Stage 5: Rearing, bilateral forelimb 
clonus, loss of balance and falling, status epilepticus (SE). If mice did not show signs of SE 
within 45 min of pilocarpine injection, a second dosage of 170 mg/kg body weight was 
applied. After 40 min in SE, diazepam (Roche) 4mg/kg body weight was injected s.c. to stop 
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the convulsion. Diazepam injection was eventually repeated after 30 min until the 
convulsions stopped. Each animal was placed on a warming pad and given liquids according 
to weight loss during the treatment. For the following two days, animals received oral glucose 
and soaked food. 
 
3.15.3 The kainate model of epilepsy 
Kainate injection into the mouse brain was performed by standard procedures of the Institute 
of Neurology in cooperation with Peter Bedner. For intracortical kainate injections, mice were 
anesthetized with a mixture of Medetomidine (Novartis) and Ketamine (Pfizer) and placed in 
a stereotactic frame equipped with a manual microinjection unit. The skull was prepared as 
detailed in the transplantation section. A 0.7 mm hole was drilled into the skull at coordinates 
1.9 mm anterior, 1.5 mm medial und 1.8 mm depth. 70 nl of a 20 mM solution of kainic acid 
(Sigma) in 0.9% sterile NaCl were stereotactically injected into the cortex just above the right 
dorsal hippocampus using a microsyringe equipped with a micrometer screw. Each injection 
was performed over a period of two minutes. After injection, the canula is left for two 
additional minutes in situ to limit reflux along the canula track. Skull surface electrodes for 
EEG measurements were implanted directly after kainate injection. Telemetric implants were 
placed subcutaneously on the right abdominal region with two monopolar leads connected to 
stainless steel screws of 2 mm length positioned bilaterally 1.5 mm from sagittal suture and 
1.9 mm posterior. The leads were covered with dental cement, the sculp incision sutured and 
anesthesia stopped with Atipamezol (Pfizer). Mice were kept warm under a heating lamp until 
complete recovery from anesthesia and injected with 4 mg/kg body weight Carprofen i.p. 
(Pfizer) for 3 days. The telemetry system used consisted of a transmitter implant (TA10EA-
F20; DSI), which telemeters EEG data from the mice to the receiver (RPC-1; DSI), further 
processed to a data exchange matrix. Data was analyzed using Dataquest ART software 
(DSI). 
 
3.15.4 The kindling model in mice 
All kindling experiments were performed by Robrecht Raedt and Lisa Thyrion from the group 
of Paul Boon at the University Hospital of Ghent, Belgium, with animals previously 
transplanted in Bonn. Mice were placed in a stereotactic frame. After exposure of the skull, 
eight small burr holes were drilled for the placement of anchor screws and electrodes. Two 
epidural electrodes were used for the recording of surface EEG. One was placed on the left 
side of the skull at the height of the frontal cortex and one on the left side at the height of the 
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parietal cortex. One epidural electrode was placed at the height of the sutura lambdoidea and 
was used as reference/ground electrode. A quadripolar registration/stimulation electrode was 
inserted in the right hippocampus, 2.9 mm posterior to bregma, 3 mm to midline and 3 mm 
depth from dura. In the remaining four burr holes, anchor screws were placed to fix the 
electrodes on the skull by dental cement. All electrodes were lead to a connector that could 
be attached to the EEG cables. 
Following surgery, mice were allowed to recover for at least 1 week. The after-discharge 
threshold (ADT) was determined by application of 1 sec train of 1 msec biphasic rectangular 
pulses at 60 Hz beginning at 60 μA; additional stimulations increasing by 20 μA were 
administered at 1 min intervals until an electrographic seizure lasting at least 5 sec was 
detected on the EEG. Subsequently, experimental animals were stimulated twice each day at 
a stimulus intensity 100 μA above the ADT, with an interstimulus interval of at least 4 hr until 
three consecutive seizures of class 4 or greater with limb clonus and/or tonus lasting at least 
12 sec were evoked. The behavioral manifestations of seizures were classified according to 
a modification of Racine's classification (Racine, 1972): 1, facial clonus; 2, head nodding; 3, 
unilateral forelimb clonus; 4, rearing and bilateral forelimb clonus; 5, rearing and falling (loss 
of postural control); 6, running and bouncing; and 7, tonic hindlimb extension. Control 
animals included buffer-injected as well as wildtype cell-transplanted mice.  
The duration of all ADs was also measured on the EEG. To check for a retained kindling 
response, animals were retested one and 2 weeks after the end of the acquisition phase. On 
these retest days ADT, seizure stage and afterdischarge duration (ADD) were evaluated.  
 
3.15.5 Transcardial perfusion and immunohistochemical analysis 
Anesthetized mice were opened along abdomen and thorax. A canula was put into the left 
ventricle of the heart and the right atrium was opened with a small cut. After rinsing of the 
blood system with 20 ml of PBS, the animal was perfused with 4% PFA until limbs were 
fixed. The brain was removed and postfixed at 4°C in 4% PFA overnight and cryoprotected in 
30% sucrose solution for 48 h. The tissue was embedded into TissueTek (Weckert Lab.), 
frozen and cut into coronal sections 30 μm thick using a cryostat (Leica) at −20°C, mounted 
on slides, air dried, frozen, and stored at −80°C until use. 
 
3.16 Hematoxylin and eosin stain 
For histological analysis of brain tissue sections, hematoxylin and eosin (H&E) stain was 
applied. Sections were first dried after thawing and incubated for 2 min in PBS. After 5 min in 
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hematoxylin solution (Sigma), sections were washed for 5 min under streaming tap water. 
Eosin solution (Sigma) was applied for 30 sec, followed by 6 washing steps in 100% ethanol, 
3 washing steps in isopropanol and 3 washing steps in xylol. After removal of xylol by careful 
draining of the glass slide, sections were embedded with Cytoseal (Microm). 
 
3.17 Gene expression analysis 
For gene-expression microarrays, mRNA samples of lt-NES cells and its derived neurons 
enriched via DCX-labeling (Ladewig et al., 2008) were isolated using an mRNA extraction kit 
(Qiagen) according to the manufacturers’ instructions. Samples were analyzed in duplicates 
on the HumanHT-12 v4 Expression BeadChip (Illumina). RNA samples were handled 
following Illumina's laboratory guidelines. Data processing was performed using 
GenomeStudio V2010.3 Gene Expression Module (V1.8). Data normalization was performed 
following previously published protocols (Müller et al., 2008; Müller et al., 2011). Briefly, raw-
probe and gene-level data were extracted without background subtraction, selecting those 
probes with a detection P value of <0.01 as computed by GenomeStudio and quantile-
normalized the resulting probe-intensity values across the data set (Barnes et al., 2005). 
 
3.18 Statistical analysis 
Quantitative data was generated in biological replicates. Means and standard deviations (SD) 
were computed using Microsoft Excel and GraphPad Prism software. All results presented as 
bar graphs show mean ± SD. Student’s t test was performed to determine whether a 
significant difference exists between groups (*p <0.05; **p<0.01; ***p <0.001). 
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4 Results 
4.1 Genetic manipulations in human neuroepithelial-like stem cells for the 
generation of modified neuronal cultures 
Long-term self-renewing neuroepithelial-like stem (lt-NES) cells represent a stable 
intermediate stem cell population between pluripotent stem cells and differentiated neuronal 
cultures that can be generated from any hES- and iPS cell line, self-renew in a virtually 
unlimited fashion and stably give rise to mature cultures of postmitotic human neurons (Falk 
et al., 2012). Human long-term self-renewing neuroepithelial-like neural stem (lt-NES) cells 
were established from hESC or iPSC lines as previously described (Koch et al., 2009). 
Homogenous lt-NES cell lines were cultured in the presence of FGF2, EGF and B27. Upon 
growth factor withdrawal, lt-NES gave rise to a dominant fraction of neurons expressing beta 
III tubulin, while the prolonged differentiation additionally promoted differentiation into 
astrocytes characterized by GFAP expression as well as oligodendrocytes expressing O4. 
Growth capacity as well as the differentiation potential in these cells is stable for more than 
100 passages, thus allowing genetic manipulation and propagation at the neural stem cell 
state. 
Due to their ability for clonal growth in culture, lt-NES cells are amenable to convenient and 
quick genetic manipulation enabling the derivation of poly- as well as monoclonal cell lines. In 
this thesis, two different approaches of genetic manipulations to generate monoclonal cell 
lines were used; first the correction of an expanded allele to its wildtype variant by the 
application of engineered adeno associated virus (AAV), and second, the biallelic destruction 
of a gene with zinc finger nucleases (ZFN). 
 
4.2 Generation of gene-corrected neural stem cells from MJD patient-derived 
iPS cells 
Our lab recently generated iPSC-derived lt-NES cells from patients suffering from Machado-
Joseph-Disease (MJD) and healthy controls (Koch et al., 2011). In MJD, an expansion of 
CAG repeats in the ATXN3 gene is translated into an expanded poly-glutamine (PolyQ) tract 
in its gene product ataxin-3. MJD-lt-NES cells and healthy controls (Ctrl-lt-NES cells) can be 
kept in culture as a homogenous population and upon growth factor withdrawal give rise to 
mature neuronal cultures. Importantly, it was found that MJD-neurons form SDS-insoluble 
microaggregates of ataxin-3 upon excitation with the neurotransmitter L-glutamate. Such 
microaggregates are discussed to represent an early manifestation of pathological protein 
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processing that culminates in the formation of nuclear ataxin-3-containing inclusions and 
neuronal degeneration (Chai et al., 2001; Williams et al., 2009) The following part shows the 
correction of the expanded disease-associated allele of the ataxin-3-coding gene ATXN3 in 
MJD-lt-NES cells using a site-directed AAV system. Following transduction and selection of 
gene-corrected lt-NES cells, healthy neurons could be generated that represent an isogenic 
control population for direct comparison. 
 
4.2.1 Successful generation of AAV-vectors for gene correction of elongated ATXN3 
gene variants 
The ATXN3 gene consists of 12 exons, of which exon 10 contains a polyglutamine encoding 
CAG repeat motif commonly 13-36 repeats in length. Elongation of this polyQ stretch in its 
gene product ataxin-3 is believed to cause Machado-Joseph Disease (MJD). 
PCR analysis of exon 10 showed two alleles of about the same size in the control cells 
whereas the patient-derived cells contained one long allele harboring the mutation (Fig. 
4.1a). Sequencing of the PCR products of the patient-derived cells revealed one allele 




Figure 4.1: MJD-patient-derived lt-NES cells and their suitability for AAV-transduction 
a: PCR amplification of exon 10 of the ATXN3 gene shows two different alleles in control and MJD-
derived lt-NES cells respectively, representing different CAG repeat numbers. The control cells repeat 
lengths are both in physiological range while MJD cells show one expanded allele. b: Sequencing of 
the PCR products reveals 22 CAG repeats for allele 1 and 74 CAG repeats for allele 2 of MJD cells. c: 
lt-NES cells can be transduced by AAV particles with stable integration into the cells genome as 
shown by a GFP-expressing control vector. 
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Recombinant AAV vectors can be engineered for site-directed integration, using gene-
specific homology arms. From previous experiments it was known that AAV particles of 
subtype 2 are able to transduce lt-NES cells and can integrate permanently into the cell 
genome (Fig. 4.1c). Furthermore, RT-PCR confirmed that ATXN3 is actively transcribed 
already in lt-NES cells, which allows selection with the chosen targeting strategy. 
AAVs were generated to specifically target the ATXN3 locus in order to replace the elongated 
allele with the unaffected allele from the same patient. The downstream homology arm 
carried exon 10 in its wildtype variant (Fig. 4.2, green) and adjacent intronic sequences 
(gray), while the upstream homology arm consisted only of intronic sequences. Both 
homology arms flank a floxed SEPT-selection cassette. The SEPT cassette consists of a 
splice acceptor (SA), an internal ribosome entry site (IRES), a neomycin resistance (Neo) 
gene and a polyA-signal (pA) allowing selection with G148 when the cassette is integrated in 
an actively transcribed locus. In turn the full-length gene is not expressed anymore from this 
allele. Consequently, to regain expression of the corrected allele the cassette had to be 
excised by Cre recombinase. 
To facilitate recognition of corrected and original wildtype alleles, the targeting vector was 
further modified by incorporating an exchange of one adenosine to guanosine within exon 10, 
downstream of the CAG repeats, using the Quikchange® mutagenesis kit (Stratagene). This 
modification was a silent mutation that did not change the translated amino acid but enabled 
discrimination of both alleles on genomic DNA and mRNA level. Sequencing of the modified 
targeting vector confirmed successful mutagenesis. 
 
4.2.2 AAV vectors targeted the elongated polyQ-allele site-specifically 
AAVs were produced in AAV-293 cells and cotransfection with GFPmax allowed optical 
confirmation of successful calcium phosphate transfection. After transduction of around 
750.000 MJD-lt-NES cells with AAV particles and two rounds of selection with G418, 220 ± 
40 clones could be gained. Due to the high specificity for its target locus and the use of the 
promoter-less SEPT cassette, which only allows G418 expression when integrated into an 
active locus, a large number of positive clones was expected. Screening for targeting events 
was performed with PCR for exon 10 of ATXN3 gene, using an amplicon not overlapping with 
the viral vector to avoid false-positive results. Of the 60 clones analyzed by PCR, 58 showed 
the loss of the longer, pathogenic allele (Fig. 4.3a shows 3 representative examples). To 




Figure 4.2: Gene correction strategy for the ATXN3 gene with adeno-associated viral vectors. 
 
 
Indeed, analysis for ataxin-3 also showed a loss of the polyQ-elongated protein variant for all 
22 clones analyzed (Fig. 4.3b shows 3 representative examples). Southern blotting with 
probes for the G418 resistance gene showed that in every second clone, only one viral 
integration occurred (Fig. 4.3c). Additionally, at the position of base modification in the 
targeting vector, sequencing reveals a mosaic signal for adenosine and guanosine at 
equimolar ratio (Fig. 4.3d), indicating the same amount of both variants within the genome 
and thus only one integration of viral sequence into the cells. Taken together, these results 
confirmed the integration of the targeting vector in the genome at the desired location while 
unwanted off-target integrations seemed rare. Based on these findings, it was concluded that 
the generated AAV integrates with high specificity into the desired locus, disrupting the 
pathogenic allele of the ATXN3 gene. 
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Figure 4.3: Site-specific targeting of AAV vectors into the expanded allele of ATXN3 
a: PCR amplification of exon 10 of the ATXN3 gene reveals the diminishment of the expanded allele in 
96,7% of PCR-screened clones. b: Western blotting confirms the absence of the pathogenic 58 kD 
protein variant of ataxin-3 after AAV application in all analyzed clones. c: Southern blotting was used 
to check for multiple viral integrations. Probes for the G418 resistance of the viral vector were used, 
resulting in no signal in control- and MJD cells. Half of the clones showed only one integration. These 
were used for genomic sequencing. d. Sequencing of the part of exon 10 that was mutated in the 
targeting vector showed equimolar amounts of adenosine and guanosine at the modified base. 
Adenosine originated from the physiological, unaltered shorter allele while guanosine originated from 
the viral variant which substitutes for the pathogenic, longer allele. This again confirmed that only one 
viral integration occurred while PCR and western screens indicated the correct site of integration. 
 
 
4.2.3 Efficient removal of selection cassette by Cre transduction 
As long as the selection cassette is integrated in front of the corrected exon 10, no functional 
protein can be generated form this allele as the splice acceptor diverts transcription to the 
G418 resistance gene. The cassette is flanked with loxP sequences, allowing its excision 
with Cre activity. To remove the integrated selection cassette for re-expression of ATXN3 
from the recombined allele, a Cre-coding modified mRNA was transfected twice. Western 
blotting 12 hours after Cre-mRNA-transfection of clones showed an increase of the total 
protein levels of wildtype ataxin-3 at ~ 42 kD (Fig. 4.4a). Quantification of wildtype ataxin-3 
increase ranged from 20% to 80% (presumably dependent on transfection efficiencies, Fig. 
4.4b). A fragment of ~ 30 kD which matches the expected protein size of truncated ataxin-3 
due to the integration of the SEPT cassette is diminished after Cre treatment (Fig. 4.4a). This 
observation supports the idea of physiological function of both alleles; prior to Cre 
application, the targeted allele is not functional leading to a stronger translation of both alleles 
to generate sufficient amount of protein. As soon as the targeted allele gives rise to functional 
protein, the higher translation leads to an increase in ataxin-3 protein. Efficient excision of the 
SEPT cassette was further validated by genomic PCR. In cells not transfected with Cre-
mRNA a PCR product of ~ 2000 bp is amplified from the wildtype allele and the allele 
containing the SEPT cassette leading to two PCR products of approximately the same size, 
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which could not be separated by gel electrophoresis. Following Cre-transfection the SEPT 
cassette is excised leading to a smaller PCR product of ~ 400 bp (Fig. 4.4c). To validate 
functional expression of both alleles, mRNA of corrected MLD-lt-NES cells was extracted and 
subsequently transcripted into cDNA. Sequencing of the previously modified base position of 
the ATXN3-mRNA transcript revealed a mosaic signal of adenosine from the wildtype allele 
and of guanosine from the virus-derived corrected allele (Fig. 4.4d). The equimolar amount of 
both signals indicates a physiological and balanced transcription of mRNA from both alleles. 
Based on these findings, it was concluded that the chosen approach resulted not only in the 
diminishment of the pathogenic allele but also in a functional gene correction with expression 
of physiological protein from both alleles. 
 
Figure 4.4: Excision of the selection cassette with Cre activity to regain a functional allele 
a. Western blotting of clones 12 h after Cre-mRNA-transfection shows an increase of the total protein 
levels of wildtype ataxin-3 at ~ 42 kD. b. Quantification of wildtype ataxin-3 increase ranges from 20% 
to 80% (presumably dependent on transfection efficiencies). A fragment of ~ 30 kD which matches the 
expected protein size of truncated ataxin-3 due to the integration of the SEPT cassette is diminished 
after Cre treatment. c. Efficient excision of the SEPT cassette was further validated by genomic PCR. 
In cells not transfected with Cre-mRNA a PCR product of ~ 2000 bp is amplified from the wildtype 
allele and the allele containing the SEPT cassette leading to two PCR products of approximately the 
same size, which could not be separated by gel electrophoresis. Following Cre-transfection the SEPT 
cassette is excised leading to a smaller PCR product of ~ 400 bp. d. Sequencing of cDNA of corrected 
and Cre-transfected cells showed mosaic signal at the position of base modification of the targeting 
vector indicating generation of mRNA from both alleles to the same amount.  
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4.2.4 Characterization of morphology and marker expression reveal no significant 
alterations despite genetic manipulation 
It was further validated whether genetic manipulations, the selection and clonal propagation 
resulted in changes in the differentiation potential and marker expression of isolated clones. 
Therefore, the morphology and marker expression of gene corrected lt-NES cells and their 
differentiated progeny were analyzed in parallel (Fig. 4.5a). The uncorrected MJD-lt-NES 
cells showed a polar, rosette-like structure and expressed the neural stem cell markers 
Nestin and Sox2 as well as rosette markers DACH1 and PLZF. The tight junction protein ZO-
1 is expressed at the luminar side of the rosettes (Fig. 4.5a). After growth factor withdrawal, 
these cells differentiate into a major fraction of beta III-tubulin(+) and MAP2ab(+) neurons 
and a minor fraction of GFAP(+) astrocytes (Fig. 4.5b). The gene corrected MJD(corr)-lt-NES 
cells (depicted are representative stainings of K2) show comparable morphological 
characteristics, expression of stem cell and rosette markers. 
 
Figure 4.5: Gene targeting does not influence the ability of MJD(corr) cells to differentiate. 
a. The uncorrected MJD-lt-NES cells show a polar, rosette-like structure and express the neural stem 
cell markers Nestin and Sox2 as well as rosette markers DACH1 and PLZF. The tight junction protein 
ZO-1 is expressed at the luminar side of the rosettes The gene corrected, MJD(corr)-lt-NES cells 
(depicted are representative stainings of K2) show comparable morphological characteristics, 
expression of stem cell and rosette markers b. Four weeks after growth factor withdrawal, cells of both 
populations differentiate into a comparable number of beta III-tubulin(+) and MAP2ab(+) neurons and 
a minor fraction of GFAP(+) astrocytes. Scale bars: lt-NES cells: 50 µm, diff. neurons: 200 µm.  
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Four weeks after growth factor withdrawal a comparable number of the cells expressed 
neuronal and glial antigens. Thus, the viral targeting strategy, selection of clones and Cre 
treatment did not significantly alter the characteristics of MJD(corr)-lt-NES cells. 
 
4.2.5 Gene corrected MJD-lt-NES cells no longer form microaggregates 
After glutamate induced activation of MJD-neurons, an insoluble fraction of ataxin-3-positve 
smear could be detected in western blot (Fig. 4.6). These microaggregates are very likely to 
be the first detectable signs of defects in protein degradation and accumulation of misfolded 
proteins, which finally leads to the loss of frequently used neuron populations in MJD 
patients. As a consequence, the microaggregate formation can be seen as one of the 
hallmarks of MJD pathology. Neurons made from control lt-NES cells, MJD-lt-NES cells and 
two corrected MJD-lt-NES cells were subjected to two 30 min-stimuli of glutamate-induced 
activation. Protein lysates were gained 24 h later and separated into Triton X-100-soluble, 
SDS-soluble and SDS-insoluble fractions as described (Koch et al., 2011). MJD-neurons 
showed several prominent fragments of about 25-45 kD and a high molecular smear 
indicating the presence of fragmented and aggregated ataxin-3 in these cultures (Fig. 4.6). 
Control cells and corrected clones (K1+K2) shown have no ataxin-3-positive fragments in the 
formic acid fraction. As microaggregate formation is an important biochemical phenotype of 
MJD-lt-NES cell-derived neurons, the normalization to physiological value is a good indicator 
for a full functional rescue of patient-derived cells. 
 
Figure 4.6: Gene corrected MJD-Neurons no longer form microaggregates. 
The most important biochemical difference between neurons generated from control cells and those 
from MJD cells is the formation of SDS-insoluble, Ataxin3-positive high molecular smear. This smear 
is considered to consist of microaggregates, the first step in the formation of aggregated protein 
plaques within the cells. These microaggregates can only be detected in neurons, not in neural stem 
cells or their glial progeny. Furthermore, activation of neurons by glutamate-treatment is essential as 
seen above. Arrows indicate ataxin-3 variants present in the cells. Control cells have both alleles of 
similar size, forming one large signal, while in MJD cells, the variant with expanded polyQ tract is seen 
in a signal of higher protein weight. The SDS-insoluble fraction (FA for formic acid) contains ataxin-3-
containing smear after glutamate-treatment in MJD cells. After gene-correction, only one ataxin-3 
protein variant is seen in the TX100 lane. Shown are results for two different clones. Following 
glutamate treatment, no microaggregate formation could be observed. 
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4.3 Therapeutic intervention in epilepsy: In vitro generation and validation of 
an adenosine releasing neuronal cell population 
4.3.1 Zinc-finger nuclease-mediated knock out oft he adenosine kinase gene results 
in adenosine-releasing neural stem cells 
Adenosine is a potent suppressor of excitatory neural transmission and has been shown to 
inhibit seizure activity upon direct delivery into the central nervous system (Li et al., 2007b). 
The second targeting project aims at exploiting human stem cell-derived neurons for activity-
dependent release of adenosine to the epileptic hippocampus. To that end, both alleles of the 





Figure 4.7: Disruption of the ADK gene by zinc finger nucleases. 
a. Position of zinc finger nuclease binding sites within exon 5 of the ADK gene, cleavage site is 
indicated by arrows. ZFN 18337 and 18781 bound upstream of the cleavage site, ZFN 18339 
downstream of it. b. Sequencing of the target locus revealed a homozygous deletion of 1 bp in 82.4% 
of the 148 analyzed clones. c. This deletion led to a frame shift resulting in premature disruption of 
translation (marked by asterisk). The accruing protein lacks all catalytic domains, resulting in a 
complete loss of ADK activity. Translated sequence differing due to frame shift is marked in yellow. d. 
Western blot analysis confirmed the absence of adenosine kinase. No shorter variants could be 
detected. e. The remaining 17.6% of clones gained showed the following alterations: 4.1% with an 8 
bp deletion, 3.4% with a 7 bp deletion, 5.4% with differing heterozygous alterations and 4.7% with the 
integration of differing long DNA fragments as shown here by a large product in the screening PCR. 
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Depletion of ADK was expected to result in elevated intracellular adenosine levels and thus 
increased basal release of adenosine via equilibrative nucleoside transporter (ENT). In 
neurons, additional activity-dependend release was described. For the functional disruption 
of ADK, three different zinc finger nucleases (ZFN) of Sangamo (Richmond, USA) were 
used, directed against exon 5 of the ADK gene. The three ZFNs formed two different pairs, 
binding the same target locus with its DNA-binding zinc finger domain. Dimerization of its 
double strand break-inducing nuclease domain is necessary for target cleavage. The cellular 
machinery for non-homologous end joining (NHEJ) is involved in repairing the double strand 
break, but this mechanism is error-prone and can thus result in disruption of the target gene.  
Plasmids coding for zinc finger nucleases were electroporated into lt-NES cells derived from 
the I3 line. ZFNs 18337 and 18781 bound upstream of the cleavage site inside exon 5 of the 
ADK gene, while ZFN 18339 bound downstream of it (Fig. 4.7a). After binding their target 
sequences, the close proximity between two ZFNs leads to induction of nuclease activity at 
positions indicated by arrows (Fig. 4.7a). Without the addition of a selectable marker, to 
enrich positively targeted cells it was yet possible to exploit the enzymes ability to metabolize 
adenosine analogues like 8-Chloro-Adenosine and 8-Chloro-cAMP. These two analogues 
are transformed to cytotoxic variants by metabolization through ADK. Only cells without a 
functional ADK would survive the selection process and single clones could be derived. 
Application of chemoselection for 3 weeks was sufficient to eliminate all untargeted cells. 
DNA from single clones was isolated and examined for alterations in the target locus of the 
ZFNs. Sequencing revealed a homozygous deletion of 1 bp in more than 82% of the 148 
analyzed clones. (Fig. 4.7b) This deletion leads to a frame shift resulting in premature 
disruption of translation (indicated by asterisk, Fig. 4.7c). The accruing protein lacks all 
catalytic domains, resulting in a complete loss of ADK activity. Western blot analysis 
confirmed the absence of adenosine kinase of normal size, while truncated variants could not 
be detected on the western blot (Fig. 4.7d). Despite the above-mentioned 1 bp deletion, most 
abundant variations were found to be deletions of 8 and 7 bp. The remaining 10% of clones 
showed either heterozygous alterations as seen by the mixed, double signals in the 
sequence occurring after the site of double strand break induction (Fig. 4.7e) or the 
integration of large fractions of random DNA pieces. 
As previously reported (Gupta et al., 2011), the application of zinc finger nucleases carries 
the risk of off-target cleavage. High-resolution SNP-analysis was carried out to check for 
chromosomal  abnormalities. Many  of the  derived  clones  showed duplications  or deletions  
of chromosomes and few had a massive accumulation of such modifications (Fig. 4.8a). 
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Figure 4.8: Selection of clones without off-target damages. 
a. Full genome-SNP analysis of an ADK-knock out clone showing massive chromosomal changes like 
duplications (chromosomes 1, 2, 3, 4, 7 13, 14, 16, 19, 20, 21 and X) and deletions (chromosomes 
9,10, 17, 18, 20 and 21). b. Full genome SNP analysis of an ADK-knock out clone without detectable 
alterations that resulted from the ZFN targeting. The deletion in chromosome 2 was already present in 
the founding cell line derived from I3 ES cells. c. Morphology and marker expression of ADK-/- clone B 
did not differ from wildtype cells in the neural stem cell state with rosette-like appearance and the 
expression of Nestin and Sox2. After 4 weeks of differentiation, MAP2ab- and ßIII-tubulin neurons as 
well as GFAP-positive astrocytes could be detected which indicated a differentiation potential normal 




Chromosomal abnormalities are a major risk factor for possible tumor formation. For grafting 
into animals it is important to have a cell population that is not prone to malignancy, for which 
reason clones without detectable genetic alterations (Fig. 4.8b) were selected before moving 
on. The deletion on chromosome 2 seen in all SNP analysis was already present in the 
founder cell line I3. It is not related to the application of ZFNs on the cells and clone B was 
used for the following experiments. 
The chosen clone of ADK-/- lt-NES cells could be maintained as a homogenous population of 
Sox2- and Nestin-positive neural stem cells, morphological identical to the founder cell line 
and expressing the same markers. Following growth factor withdrawal, these cells efficiently 
generated ßIII-tubulin- and MAP2ab-positive neurons and GFAP-positive astrocytes (Fig. 
4.8b). 
 
4.3.2 ADK stays expressed after differentiation into neurons 
The efficiency of secreted adenosine not only depends on its removal by metabolization 
through the enzymes adenosine kinase and adenosine deaminase but also on the 
expression of the respective adenosine receptors. To check if the receptors needed for 
adenosine-mediated inhibition and the key metabolizing enzymes are still present after 
differentiation of lt-NES cells into neurons, expression profile analysis was performed 
comparing lt-NES cells with their neuronal progeny generated by a neuron-enrichment 
method established earlier at our institute (Ladewig et al., 2008). Transcripts of adenosine 
kinase (ADK), adenosine deaminase (ADA), and adenosine receptors A1 (ADORA1), A2A 
(ADORA2A), A2B (ADORA2B) and A3 (ADORA3) were evaluated as seen in Fig. 4.9. In lt-
NES cells, ADK and ADA genes were highly expressed, but diminished after neuronal 
differentiation. Contrary, expression of A1 and A3 receptors was increased in neuronal 
progeny, while transcripts for the A2 receptor subtypes A and B are hardly detectable in both 
populations. Taken together, action of adenosine is expected to be intensified in 
differentiated neuronal cultures, as the amount of metabolizing enzymes decreases while 





Figure 4.9: Expression of adenosine-related transcripts in lt-NES cells and neurons. 
a. Comparison of relative transcript expression of adenosine receptors A1, A2A, A2B and A3 (ADORAx), 
adenosine kinase (ADK) and adenosine deaminase (ADA) in lt-NES cells (blue) and neurons (red). 
ADK and ADA are highly expressed in neural stem cells but down regulated after differentiation. 
ADORA1 and ADORA3 transcripts showed an increase after induction of neuronal commitment while 
both ADORA2 transcripts are not present. b. Fold change in expression after maturation of lt-NES 
cells into neurons. Transcript detection performed with n=2 probes per transcript. 
 
 
4.3.3 Adenosine kinase deficient cells release adenosine in vitro 
After confirming the ADK deficiency on the genomic and proteomic level, adenosine 
distribution by the ADK-/- lt-NES cells was assessed by collecting cell culture supernatants 2, 
8 and 24 hours after media change to analyze for adenosine content. As the second 
metabolizer of adenosine, the adenosine deaminase is still present in the cells, its inhibitor 
EHNA (50µM) was added to facilitate measurement. This limitation of the in vitro 
measurement was found to be neglectable in transplantation approaches as surrounding 
cells should immediately take up adenosine. Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) revealed an up to 200-fold increase in adenosine release 
compared to wildtype cells, and an accumulation over time (Fig. 4.10a) Different clones of 
undifferentiated ADK-/- lt-NES cells released comparable amounts of adenosine while 
differentiated cultures showed variability between different clones (Fig. 4.10b).  
It was suspected that the different ratio of neurons and astrocytes within differentiated 
progeny could be a reason for the differences in adenosine output. Therefore, neuron- or 
astrocyte-enriched differentiated cultures were generated and again adenosine levels 
evaluated (Fig. 4.10c). Astrocytes showed a lower basal adenosine release compared to 
neurons, disagreeing with results from previous work with primary rat cultures (Parkinson et 
al., 2002). Glutamate lead to an increase of adenosine release in both populations, whilethe 
effect in neurons was much more prominent (Fig. 4.10d). These observations stand in line 
with previous reports about activation-dependent release of adenosine (Lovatt et al., 2012). 
 72 
Based on previous data, a total of 50.000 cells was calculated to be sufficient to yield an anti-





Figure 4.10: Adenosine release of ADK-/- cell cultures. 
a. Comparison of adenosine release into the culture media of wildtype lt-NES cells, ADK-/- lt-NES cells 
and their differentiated progeny at 2, 8 and 24 h. While adenosine release by wildtype cells is at the 
detection limit, ADK-/- cells deliver adenosine into the media, where it accumulates over time (n=3 
each). b. Various clones of ADK-/- cells showed comparable amounts of released adenosine while 
after 4 weeks of differentiation the amounts differed largely (n=3 each). c. Astrocyte- or neuron-
enriched cultures of ADK-/- lt-NES progeny. Both cultures were stained for beta III-tubulin as neural 
marker and GFAP as astrocytic marker showing high enrichment for either cell population. Pie chart 
on the right states the composition of each culture after counting of 3 fields of vision (Astrocyte-
enriched: 2.7% neurons, 88% astrocytes, 9.3% other cells. Neuron-enriched: 78.9% neurons, 8.8% 
astrocytes, 12.3% other cells.) Scale bar = 50 µm. d. Adenosine distribution into supernatants of 
neuronal and astrocytic cultures of WT and ADK-/- cells were evaluated under standard conditions and 
following stimulation with glutamate. Glutamate generally induced an increase in adenosine efflux, 
which is especially prominent in ADK-/- neuronal cultures. Statistical analysis: *, p < 0.05; **, p < 0.01; 





4.4 In vivo application of adenosine-releasing cell populations 
4.4.1 lt-NES cells transplanted in the mouse hippocampus show migration and long-
term survival  
Initial transplantations of lt-NES cells (wildtype and ADK-/-) were delivered to the 
hippocampus of Rag2-/- C57/Bl6 mice to check for migration and survival of grafts. Another 
important question was how durable these immunodeficient animals would be, as Rag2-/- 
mice have no functional adaptive immune response, which could be problematic especially 
for animals with open head wounds after surgery. 
A total of 50.000 lt-NES cells were stereotactically delivered to the right hippocampus. Mice 
recovered well from surgery and around 12 weeks later were sacrificed for histological 
analysis. Stainings for human axonal microfilaments and human nuclei showed the 
distribution and maturation state of grafted neural stem cells. Lt-NES cells tended to form 
transplantation cores of fairly undifferentiated cells at the center of the graft, while cells in the 
periphery differentiated faster and migrated into the host tissue. Cells showed robust survival 
with axonal projections across long distances within the ipsilateral hemisphere, approaching 
the CA3 region, corpus callosum, motor cortex and thalamus. Projections of human neurons 
could also be found in the fimbria and the contralateral hippocampal pyramidal cell layer (Fig. 
4.11a), following a projection pattern typical for commisural hippocampal axons. 
Stainings for human synaptophysin showed dotty signals that were arranged like chains (Fig. 
4.11b) indicating the functional connectivity with neural dendrites of the host tissue. Based on 
these findings, it was concluded that lt-NES cells after grafting differentiate into mature 
neurons, with axons migrating along intrinsic pathways. Long-term experiments showed that 





Figure 4.11: Grafting of lt-NES cells into the mouse hippocampus. 
A total of 50.000 lt-NES cells were grafted into the right hippocampus as indicated by the red arrow. 
12 weeks after surgery, animals were sacrificed for immunohistochemical analysis. a. Coronal 
sections of brain slices stained for human nuclei in white and human axonal neurofilament HO14 in 
red, counterstained with DAPI in blue, clockwise: A large cluster of undifferentiated lt-NES cells could 
be detected at the grafting site (1), while at the periphery most of the cells differentiated into mature 
neurons, that migrated along intrinsic axon guidance pathways throughout the host’ tissue as shown 
by yellow lines in the overview. Human neurons could be detected at the transplantation site (1), 
beneath the dentate granule cell layer of the ipsilateral hippocampus (2), the corpus callosum (3), the 
entorhinal cortex (4) and also in CA3 regions of the contralateral hippocampus (5). Scale bars: (1) = 
500 µm, (2)-(5) = 50 µm. b. Coronal section of the contralateral hippocampus stained for human 
synaptophysin showing dotted signals, indicating the establishment of functional synapses with host 






4.4.2 Application of adenosine-releasing lt-NES cells in mouse models of epilepsy 
For the therapeutic application of adenosine releasing cells, a mouse epilepsy model is a 
prerequisite for the evaluation of the system. First attempts focused on the pilocarpine model, 
which was later changed to the kainate model. Both are models for the generation of 
chronically epileptic mice, which show specific histological alterations in the epileptic 
hemisphere after application of the compound. In addition, an electric kindling model was 
used, which is used as a system for the evaluation of the process of epileptogenesis. The 
grafting of human cells made it necessary to use genetically immunodeficient mice, as the 
alternative of daily immunosuppressive injections was not an option as based on experiences 
made in our lab. 
 
4.4.2.1 Pilocarpine or kainate application to generate epileptic mice 
For the therapeutic application of adenosine releasing cells, a mouse epilepsy model is a 
prerequisite for the evaluation of the system. First attempts focused on the pilocarpine model. 
Pilocarpine is a strong agonist of glutamate receptors leading to a general activation of 
neuronal activity. It is applied systemically by subcutaneous injection into the animal 
abdomen. The survival rate using the protocol described in the method section was around 
80%, with most animal losses resulting from fulminant seizures that lead to acute death 
before status could be reached. Within the next 2 weeks, about 15% of the remaining 
animals died to unknown reasons resulting in an overall survival rate of around 60%. These 
animals showed spontaneous generalized seizures at least once a day. After the successful 
establishment of the pilocarpine protocol in normal C57/Bl/6 mice, it was used on 
immunodeficient Rag2-/- mice of the same C57/Bl/6 background, as these would be needed 
to tolerate the grafting of human cells. On the day of pilocarpine application, behavior and 
survival rates of the immunodeficient mice compared to standard mice were very similar. 
However, in the following 3 weeks, all remaining animals died for unknown reasons. In 3 
independent experiments, it was not possible to generate surviving immunodeficient mice 
with chronic seizures with survival longer then 4 weeks (Fig. 4.12). As these results indicated 
incompatibility of the pilocarpine mode and the used mouse strain, SCID/beige mice were 
subjected to the pilocarpine model. Surprisingly, this strain tolerated even very high doses of 
pilocarpine without showing signs of an epileptic status. The experiments were finally aborted 
because of severe peripheral effects of pilocarpine, which could no longer be inhibited by the 
amount of scopolamine given. Despite the successful generation of C57/Bl/6 epileptic 
animals, failure to transfer the procedure to immunodeficient mice led to the consideration to 
use kainic acid to induce chronic epilepsy 
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 Figure 4.12: Survival of mice after 
pilocarpine treatment. 
a. Kaplan-Meier survival blot of animals 
used in the pilocarpine model. Following 
three experiments with wildtype C57/Bl/6 
mice with a success rate of up to 70% in 
regard to generation of epileptic animals 
the same protocol was applied to Rag2-/- 
animals of C57/Bl/6 background. 
Immediate survival after pilocarpine 
treatment was 50-63%, while the next 3 
weeks following treatment resulted in loss 
of all immunodeficient animals. b. Tabular 




Kainic acid is a strong activator of glutamate receptors leading to immediate epileptic 
seizures and eventually to the manifestation of a status epilepticus (SE). Rag2-/- 
immunodeficient mice were subjected to kainic acid on the right hippocampus only and EEG 
electrodes were transplanted immediately afterwards in the same surgical operation. EEG 
monitoring was used to confirm when SE was reached. Two weeks after the procedure, 
exemplary histological analysis revealed prominent granule cell dispersion, a main 
histological feature of chronic epilepsy in the kainate model and also in human patients with 
chronic temporal lobe epilepsy (Fig. 4.13a, (Houser, 1990)). Within 18 days after surgery, 
mice showed repeated seizures up to the highest seizure stage Racine 5, so animals could 
be termed being chronic epileptic. Animals showed robust survival with no obvious variations 
to standard C57/Bl/6 strains. Therefore, the kainate model system was used for first 
transplantations of adenosine releasing human neural stem cells and their in vivo arising 
neurons. 
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4.4.2.2 lt-NES cells grafted into the epileptic hippocampus show enhanced 
dispersion and a trend towards reduced spontaneous seizures  
Intracerebral injection of kainate into the right hippocampus of immunodeficient Bl/6-Rag2-/- 
mice was used to induce chronic epilepsy. Two weeks after kainate treatment, a total of 
50.000 ADK-/- or wildtype lt-NES cells were transplanted into the ipsilateral hippocampus, 
along with electrodes for EEG measurements. EEG recordings were obtained for 2 weeks 
until mice were sacrificed for histological analysis. Transplanted lt-NES cells integrated well 
into the kainate-treated hippocampus and migrated along the CA1 and CA3 layers as 
depicted by staining for the human nuclear antigen (Fig. 4.13a). Remarkably, and in contrast 
to grafts into the healthy hippocampus, the cells showed pronounced dispersion without 
formation of a transplantation core. EEG recordings, supported by video analysis, were used 
to assess the total number of grade 5 seizures across 14 consecutive days. Recipients of 
wildtype cells showed an average of 27.8 seizures while recipients of ADK-/- cells had an 
average of 11.8 seizures (Fig. 4.13b). Due to a large dispersion of effects and insufficient 











Figure 4.13: Grafting of adenosine-releasing lt-NES 
cells into the kainate-treated hippocampus. 
a. Coronal section of a kainite-treated hippocampus with 
prominent granule cell dispersion. Two weeks after 
kainate treatment, a total of 50.000 ADK-/- or wildtype lt-
NES cells were transplanted into the ipsilateral 
hippocampus at the position marked by red arrow. 
Sections were stained for human nuclear antigen, 
illustrating the pronounced dispersion without formation of 
a transplantation core. Scale bars: 200 µm. b. Box blot 
diagram showing the number of grade 5 seizures across 
14 consecutive days. Recipients of wildtype cells showed 
an average of 27.8 seizures while recipients of ADK-/- cells 
had an average of 11.8 seizures. 
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4.4.3 Diagonal grafting of lt-NES cells results in distribution throughout the 
hippocampus in a kindling model of epilepsy 
As adenosine does not only have an effect as suppressor of seizures but has also been 
described to modulate epileptogenesis, we were interested whether transplanted ADK-/- cells 
would suppress epileptogenesis in a kindling model of epilepsy. To that end we kindled 
immunodeficient C57/Bl6 and Rag2-/- mice and analyzed epileptogenesis. These results were 
compared to wildtype animals. The stimulation electrode was placed into the amygdala, while 
a set of measuring electrodes was placed epidurally to enable EEG recordings. After 
determination of electrographic seizure threshold (EST), animals were kindled twice daily at 
EST until three consecutive seizures of class 4 or greater lasting at least 12 sec were 
observed to term animals fully kindled. Parameters evaluated during kindling contained 
seizure grade based on the extended scale of Racine, seizure duration and afterdischarge 
threshold (ADT). Beside a delay in the development of seizures in regard to severity and 
duration in the immunodeficient mice within days 3 to 8, there was no difference in the 
reaction to the kindling paradigm. The delay was caught up and after 3 weeks, animals of 
both groups were fully kindled with daily seizures of grade 5 First experiment with cells 
grafted into the anterior hippocampus, the same grafting site as used with the kainate model, 
were performed. Either wildtype (WT) or ADK knockout (KO) cells were grafted into the right 
hippocampus, 50.000 cells each, while control animals only received saline buffer. After two 
weeks of recovery, mice were transferred to the kindling facility and after 2 additional weeks 
of adaption, kindling was started. Using the same kindling protocol resulted in a total of 3 
Sham animals, 6 WT cell-grafted animals and 5 KO cell-grafted animals fully kindled. After 
the first two weeks, the duration and severity of seizures became very uniform, and in the 
end, no differences could be observed between differently grafted groups Histological 
analysis revealed a widespread migration of grafted cells with extensive axonal outgrowth 
into the host tissue, as judged by immunochemical staining for human nuclei and HO14 (data 
not shown). Cell maturation and survival was not affected by the kindling procedure. 
We reasoned, that the size of the graft and the inappropriate innervation of the entire 
hippocampus were responsible for the negative outcome. Ideally, a graft would distribute 
along a large portion of the hippocampal structure from anterior to posterior so that 
commissural projections would also innervate the amygdala. Due to the crescent-like, winded 
anatomy of the mouse hippocampus, the only way to achieve a grafting tract through the 
hippocampus without touching the lateral ventricle was to inject diagonally instead of 
vertically from the skull surface. It would be important not to hit the fissure between 
hippocampus and thalamus or the lateral ventricle while generating the cannula tract, or cells 
would evade into these more space-affording rooms, leaving only few of the grafted cells 
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within the hippocampal formation. From coordinates +0.9 mm posterior and +0.5 lateral to 
bregma a 45° angle from vertical and 47.5° angle from the midline was used, creating a 
diagonal injection tract aiming at a coordinate of 3.9 mm posterior to bregma (AP), 3.0 mm 
lateral to the midline (ML) and 3 mm below the dura (DV). Cells were injected during 
retraction of the cannula at a rate of 1 µl per mm and min. This enabled us to deposit the 
cells over a relatively long injection tract within the right hippocampus and adjacent to the 
stimulation electrode implantation site. 
Histological analysis of diagonally grafted animals revealed that this cell injection approach 
covered most of the dorso-ventral extent of the hippocampus by placement of the grafted 
cells into the infra-hippocampal cleft and minimized the damage to the ipsilateral 
hippocampus (Fig. 4.14a-d). From anterior to posterior, the graft followed the hippocampus 
going to ventral and lateral direction and was found at similar positions within the dentate 
gyros along its way. The Rag2-/- mice showed larger variations in skull anatomy then the 
standard C57/Bl/6 mice, which most likely resulted also in differences of brain anatomy. 
During surgery, these differences in grafting trajectory were tried to be equalized by 
measuring the distance between bregma and lambda suture and eventually adjusted the 
point of cannula entry as determined by skull coordinates measured from bregma. Still, in 
about 25% of all animals transplanted, graft position was suboptimal. This made a 
histological analysis essential, allowing to exclude animals after all experiments were 
performed. During application of the diagonal grafting technique, the loss of animals due to 
trauma or injuries was not found higher as in the classical vertical grafting approach. 
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Figure 4.14: Diagonal transplantation of lt-NES cells into the mouse hippocampus. 
The blue line indicates the trajectory of diagonal transplantation into the right hippocampus using an 
angle of 47.5° from the midline and 45° from vertical. The blue circle defines locations where human 
cells have been found in the respective section, supported by HE and immunohistological stainings as 
shown on the right.a. Coronal section 1.7 mm posterior to bregma. HE staining showed the delivery of 
cells within the inner granule cell arch of the frontal lateral hippocampal formation (H). If cells were 
also deposited within the lateral ventricle, they could be found until the upper anterior part of the 
ventricle (V). b. Coronal section 2.5 mm posterior to bregma. Immunohistological staining for human 
nuclear filament in green. The black bar indicates the stimulation electrode transplantation site. c. 
Coronal section 3.3 mm posterior to bregma. Immunohistological staining for human nuclear filament 
in green revealed grafted cells within the inner granule cell arch and in the lateral ventricle. d. Coronal 
section 3.8 mm posterior to bregma. This is the most posterior and most ventral point of cell disposal. 
Scale bars: 200 µm. Pictures on left side derived from the Allen Mouse Atlas (Lein et al., 2007). 
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4.4.4 Additional ventricular deposition of adenosine-releasing lt-NES cells results in 
an increased after-discharge threshold in a kindling model of epilepsy 
In addition to the diagonal grafting tract, it was also decided to switch the place of kindling 
from the amygdala to a position more anterior and dorsal within the hippocampus, thereby 
increasing the proximity of stimulation electrode and graft. New coordinates for 
transplantation of the stimulation electrode were 2,9 mm AP, 3 mm ML, and 3 mm DV. 
Kindling was again performed with WT cell-grafted, ADK-/- cell-grafted animals and sham 
controls, using the same parameters as for the amygdala kindling. Surprisingly, using these 
conditions resulted in a lack of afterdischarge generation in many of the animals. Of the 
sham group, 3 out of 7 animals were excluded, of the WT cell grafted group 2 out of 6 
animals and of the ADK-/- cell grafted group 2 out of 5 animals because no AD could be 
generated. As result, animal numbers for each group were only small, leading to a high 
degree of variation as seen by the large standard error values in the diagrams (Fig. 4.15a). 
Animals which only received sham buffer showed weak responses to electrical stimulation 
while animals obtaining ADK-/- cells could be kindled as in previous experiments and 
developed stage 4 seizures in adequate time. Animals grafted with wildtype cells responded 
also well to kindling but did not reach values as high as the ADK-/- group. These results were 
not of the expected outcome, as adenosine-releasing grafts should decrease the severity and 
duration of seizure events. In the next experiment, a higher number of cells was grafted to 
facilitate a possible effect. Following suggestions of the Li publication (Li et al., 2007b), an 
additional graft was deposited in the lateral ventricle. From there, cells would spread over the 
whole right ventricle and also into the fissure between thalamus and hippocampus, thereby 
supporting the intra-hippocampal graft with adenosine efflux from outside the hippocampal 
structure. The kindling of this second diagonal grafting approach was performed with the 
same parameters as before (Fig. 4.15b). In this experiment, the sham group could be kindled 
much better and reached seizure stage 4 in the fourth week, while the ADK-/- cell grafted 
group still showed stronger seizures in respect to duration or class, not supporting the thesis. 
However, animals with ADK-/- cells needed a much higher electrical stimulation to generate 
seizures, as the evaluation of the afterdischarge threshold (ADT) revealed. A higher current 
had to be applied to provoke a reaction, resulting in a seizure that was stronger and lasted 
longer than in the sham animals stimulated at lower currents (Fig. 4.15c). The increase in 
ADT was significant compared to both sham and WT cell grafted groups only in the 
experiment with diagonal grafting and ventricular deposit, while values with diagonal grafting 
tract only were much lower and more even. 
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Figure 4.15: Kindling of diagonally 
transplanted animals. 
a. Seizure class and seizure duration 
during 24 consecutive days of kindling in 
Rag2-/- mice grafted with wildtype, or 
ADK-/- lt-NES cells or buffer as sham 
control using a diagonal injection tract. 
No visual detectable seizures of the 
animals on the first 5 days of kindling 
could be observed. Especially the sham 
group did not reach seizure classes 
comparable to previous attempts. Size of 
groups: nSHAM = 4, nWT = 4, nKO = 3. b. 
Seizure class and –duration of wildtype 
or ADK-/- lt-NES cells grafted and buffer 
sham control treated animals using one 
diagonal injection tract and an additional 
ventricular deposit. Again, the sham 
group did not behave optimal without 
increase in seizure duration during the 
experiment. Size of groups:  nSHAM = 5, 
nWT = 4, nKO = 7. 
c. Afterdischarge threshold after kindling 
procedure. Left group with diagonal 
grafting only while right group had also a 
ventricular deposition of either wildtype- 
or ADK-/- cells or buffer. ADT significantly 
increased with the additional ventricular 
deposit. Due to the small animal numbers 
of the WT group, SEM is quite high, not 
allowing any significant statistical differences compared to sham control. 
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The results were subsequently correlated to the history of the brains after the experiment 
was terminated. Mouse brains showed prevalent indentations of the electrodes used, which 
were originally designed for use in much larger rats (Fig. 4.16a). All animals were analyzed 
with HE stainings to check for inflammation, scar formation or signs of intracranial 
hypertension, but no general damage to hippocampal structures could be detected. The 
grafts were found in the desired location (Fig. 4.16b), and immunohistochemical-staining was 
performed to address neuronal maturation and integration. A total of 6 animals had blood 
coagulates either at the stimulation electrode site or the cannula tract, likely resulting from 
the removal of electrodes prior to sedating the animals for fixation. No augmented presence 
of astrocytes or immune cells was observed at the cannula tract. In 3 out of 30 animals used 
in this experiment, a leucocytic invasion deriving from the dural surface electrodes, which 
proceeded into the brain tissue, was found (Fig. 4.16c). The surface electrodes were fixed 
with screws in the dura, which could have irritated the surrounding tissue, thereby provoking 
an inflammation. All these injuries were found in sham animals, only receiving buffer. One 
general problem, which was found in around 25% of all animals irrespective to the grafted 
population, was that the location and the size of the stimulation electrode led to a dissection 
of the whole hippocampal structure (Fig. 4.16d). Such a damage would very likely result in 
unexpected kindling responses. All animals that showed the mentioned obstacles were 
excluded from the experiment, but the overall result did not change. Noteworthy is, that 
besides the large cavities that were caused by the stimulation electrode, they were not 
colonized by grafted cells, which would also have very likely resulted in a kind of isolating 





Figure 4.16: Histological analysis of animals after application of full kindling protocol. 
a. Brain of a kindled mouse after removal of the skullcap. The six electrodes used in each animal left 
clearly visible dents in the brain, extending up to 5 mm into the tissue. This irritation of brain tissue is 
further shown in the following sections. b. Coronal section 2.6 mm posterior to bregma. HE staining 
showed the delivery of cells (graft is indicated by dotted line) into the hippocampus within the 
polymorph layer of the dentate gyros (DG) and the stratum lacunosum-moleculare (SLM). Overall 
structure of HC is intact beside the former location of the stimulation electrode, as seen by the large 
rupture lateral to the graft (SE). c. In two animals, leucocytic invasions of the contralateral striatum 
were found, invading the tissue from the site where subdural measuring electrodes were placed. d. In 
around a quarter of total animals, placement of the stimulation electrode dissected the whole 




5.1 AAV-mediated gene targeting in lt-NES cells 
We recently showed the generation of patient-specific neurons differentiated from lt-NES of 
patients with Machado-Joseph disease (Koch et al., 2011). Patient-specific cells show an 
elongation of CAG repeats in exon 10 of the ATXN3 gene, resulting in a polyQ-elongated 
variant of ataxin-3 protein. The first genetic modification of this study used engineered 
adeno-associated virus to exchange the expanded allele of the ATXN3 gene with its wildtype 
variant. The applied method was found to be highly efficient and resulted in clones that no 
longer possessed the pathogenic variant of ATXN3/ataxin-3 on a genomic or protein level. 
After Cre-mediated excision of the selection cassette, both alleles showed expression of the 
wildtype protein. The gene-corrected lt-NES cells had the same morphological characteristics 
as the founder cells and could be efficiently differentiated into human neurons, which is the 
cell type affected by the disease. These results show that AAV particles are a powerful tool 













It is interesting to note that before using zinc finger nucleases, targeting of the adenosine 
kinase gene was tried with AAV vectors, similar to the approach used for the ATXN3 
targeting. Yet, several attempts were not successful, very likely because of the genome 
structure of the ADK gene contains large introns bearing a lot of repetitive sequences, 
making it difficult to find long homologous sequences needed for AAV targeting (Khan et al., 
2011). Zinc finger nucleases on the contrary only need a relatively small DNA sequence to 
act site-directed, which can be a large advantage in some genes as seen with the ADK 
locus. This example already shows that despite its many advantages, AAV-mediated 
targeting is not possible in every locus to the same extent. 
The vast majority of analyzed clones generated during this study showed the exchange of 
the expanded allele against the virally offered wildtype variant, although homology to the 
allele of physiological length was higher and thus expected to consequentially be targeted 
more often. It has been reported that long tracts of CAG repeats can lead to a change in 
chromatin structure and histone packaging (Wang et al., 1994), and in yeast it was shown 
that CAG repeats increase the spontaneous exchange of unequal sister-chromatids (Nag et 
al., 2004). Such an exchange is mediated by the machinery for homologous recombination 
(Sonoda et al., 1999), which is also needed for AAV-mediated targeting (Vasileva et al., 
2006). This raises the possibility that similar mechanisms are responsible for the higher 
crossing-over efficiencies at the pathogenic allele of the ATXN3 gene. 
 
5.2 Gene corrected human neurons 
Very recently, Ellerby and coworkers presented the genetic correction of Huntington’s 
disease (HD) in iPS cells (An et al., 2012). In HD, just as with MJD, the elongation of CAG 
repeats within the HTT gene is disease-causative. Via BAC-mediated homologous 
recombination, the expanded allele was exchanged against a wildtype variant, a technique 
that proved also to be highly efficient. Other successful site-specific modifications were 
achieved either with ZFNs by the group of Jaenisch and Zou with coworkers (Hockemeyer et 
al., 2009; Zou et al., 2009) or AAV-mediated corrections by the group of Russell (Khan et al., 
2010). Although more and more examples of successful genome modification are found in 
the literature, all the above publications mentioned use pluripotent human cells. The use of 
neural stem cells as in this thesis allows a faster and easier generation of several 
monoclonal cell lines due to their clonal growth and shorter protocols to generate the 
differentiated cell type of investigation. 
The gene-corrected neurons offer an ideal isogenic control population to the pathogenic 
MJD-neurons in order to elucidate underlying mechanisms of the disease, and how an 
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elongated ataxin-3 can mediate cell death of the affected neurons. These kinds of isogenic 
populations only differing in one specific locus offer new possibilities to overcome cell line 
specific differences of non-isogenic controls that could cloak disease-relevant subtle changes 
and should lead to a better understanding of neurodegenerative disorders in the human 
system. Normally, control cells for experiments with patient-specific iPS-cell derived 
populations are from healthy individuals, without knowing if such an individual would not 
suffer from a late-onset neurodegenerative disease several decades later. Additionally, even 
monogenetic diseases like MJD are affected in their time of onset or severity by many other 
factors, which can easily be seen by comparing numbers of CAG repeats in ATXN-3 in 
patients, which can have as little as 45, while healthy individuals with up to 47 are known. In 
this overlapping region where the number of repeats alone is not sufficient to state if the 
disease will develop, a multifactorial nature which normally is more present in other diseases 
is seen. Accounting for this are SNPs or polymorphisms within the genome, of which many 
are not known or not studied enough to deduce any relations towards the disease studied. 
This means that any non-isogenic control population is a kind of black box with uncertain 
interactions with the studied genes, which can lead to false interpretation of data. A 
population only modified in one specific allele would allow the true study of functions and 
interactions of the one protein of interest.  
Without reasonable tissue sources till recently, especially cell therapies of the central 
nervous system benefit immensely from stem cell-derived options. The recent advancements 
in the generation of patient-specific cell populations via reprogramming also offer possibilities 
for regenerative therapies. The combination of patient-derived iPS cells with genetic 
correction of the disease-associated genotype creates the potential to generate autologous 
cell populations for therapy. On the way towards a general application, highly efficient 
targeting techniques are needed. As demonstrated in this study, AAV-mediated targeting in 
combination with a promoterless selection cassette enables the generation of high numbers 
of clones with a very low number of false-positives, which will help to keep screening efforts 
to a minimum.  
Importantly, the corrected MJD-lt-NES cells gave rise to mature neurons in vitro. Furthermore 
the described procedure reverses the phenotype of the diseased cells, which no longer 
showed the formation of microaggregates. Previous work with iPS- and ES-cell-derived lt-
NES cells and the transplantation of ADK-/- lt-NES as part of this thesis showed that grafting 
into mice brains results in their maturation into functional neurons, which integrate into the 
host tissue and migrate along common commissural pathways in vivo (Steinbeck et al., 
2011). These findings indicate the possibility of future cell therapeutic attempts. 
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The establishment of iPS technology enabled us to generate pluripotent cells of any person, 
and the generation of protocols to generate neural stem cell populations allowed us to 
generate unlimited numbers of human neurons. Combined application to patients suffering 
from neurological disorders gives us better possibilities to study disease mechanisms then 
ever before. The techniques presented in this thesis offer new possibilities not only for the 
elucidation of disease causation, but also perspective for curing it. The removal of disease-
associated mutations or the genetic manipulation to generate a beneficial isogenic cell 
population prevents all immunogenic rejection problems arising in cell therapeutic 
approaches. Using a patients own cells, curing them and donating them back to eventually 
“heal” the person is still a long way off, but comes closer with recent developments in stem 






Figure 5.2: Cell therapeutic approach for the central nervous system using iPS-derived, 
genetically modified neural stem cell-derived neurons. 
Fibroblasts are derived form a tissue biopsy from the patient. Under induction of pluripotency, iPS cells 
are generated, which can be differentiated into neural stem cells (lt-NESCs). They offer a population 
amenable to genetic manipulation. After enrichment of gene-corrected neural stem cells, they can 
either be directly delivered to the patients’ central nervous system to mature in vivo into neurons to 
substitute for lost cell populations, or can be prematured in culture and delivered later. 
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5.3 Zinc finger nucleases for gene targeting in lt-NES cells 
For the second approach of site-specific genetic manipulation with zinc finger nucleases, the 
aim was to achieve a biallelic destruction of the adenosine kinase gene, resulting in the 
secretion of increased levels of adenosine by these cells. ZFNs as synthetic fusion proteins 
bind with their engineered zinc finger motif domain to a defined DNA sequence. When two of 
these zinc finger nucleases come into close proximity, a double strand break can be induced. 
The needed proximity is achieved by designing two ZFN proteins with DNA-binding motifs for 
sequences at short distance to each other. The induced break can subsequently lead to 
wrong corrections by the cellular DNA repair machinery. As selection was based on the 
missing enzymatic activity, only clones with double strand breaks leading to a frame shift and 
thus an incomplete enzyme translated from both targeted alleles were gained. Multiple 
monoclonal cell lines were gained, no longer expressing functional ADK enzyme, which as a 
consequence showed an increased secretion of adenosine into cell culture supernatants. 
The destruction of genes in this manner is the easiest way to use the double strand break 
inducing activity of zinc finger nucleases. Additionally, an open double strand break facilitates 
the integration of other DNA fragments into the affected position, allowing the addition of 
genetic information. This has been successfully performed with small oligonucleotides, 
enabling introduction of single bases, for example for the exchange of amino acids within a 
gene (Chen et al., 2011a; Radecke et al., 2010). The integration of larger donors with 
multiple transgenes has also been shown, thereby offering selection capacities similar to viral 
systems but with the benefit of site-specific integration (DeKelver et al., 2010; Moehle et al., 
2007; Zou et al., 2009). In the course of this study, introduction of a larger plasmid into the 
ADK gene was also attempted by cotransfecting it together with the ZFN coding plasmids to 
gain a selectable cassette, but integration events were very rare and only monoallelic 
integrations in the desired locus could be observed (data not shown). 
To disrupt the adenosine kinase gene, the use of ZFNs was highly efficient and selection for 
targeting events by suicide drugs that needed to be metabolized through ADK to become 
toxic was comparable. If the targeted gene would be not an enzyme offering this possibility, 
enrichment for positives would become more complicated as short-term selection for 
transiently co-transfected selection markers or even the stable integration of a selection 
cassette would be needed. 
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5.4 Zinc finger nucleases (ZFNs) in comparison to Transcription activator-like 
effector nucleases (TALENs) and the Crispr/Cas9 system 
Recently, another class of custom-made nucleases for gene targeting was described: the 
transcription activator-like effector nucleases, or TALENs (Cermak et al., 2011; Li et al., 
2011). Similar to ZFNs, they consist of the same Fok1 nuclease domain fused to a DNA-
binding domain of TAL effectors, and close proximity between two of them leads to nuclease-
domain dimerization and thus induction of a double strand break. Like with zinc finger 
domains, recognition of a specific DNA sequence is achieved by generating a DNA-binding 
protein by linking together several modular TALE repeats. In contrast to zinc finger domains 
of 30 amino acids that each recognizes three base pairs, each TALE repeat consists of 34 
amino acids and recognizes only a single base pair (Boch et al., 2009; Mak et al., 2012; 
Moscou and Bogdanove, 2009). This makes the generation of new DNA binding proteins 
much easier as only 4 different modules are needed to generate TALEs of any specificity 
compared to 64 different possible modules for zinc finger domains. Several protocols are 
available that describe the rapid assembly of custom TALE repeat arrays in only a few days 
using publicly available reagents (Cermak et al., 2011; Reyon et al., 2012; Zhang et al., 
2011). In theory, development of ZFNs is also possible in a modular way, but often still needs 
a combination with 2-hybrid systems (Pruett-Miller et al., 2008) or phage display (Dreier et 
al., 2005), which is much more work intensive. This is one reason why many ZFNs used in 
the literature are industrially made, also because the involved biotech companies are rights 
holders for many proprietary methods for assembling zinc finger proteins. 
Meanwhile, TALENs are now commercially available from companies such as Life 
Technologies. As TALENs are newer to the field, they have been much less studied than zinc 
finger proteins, and continued work is necessary to fully understand the strengths and 
weaknesses of the two different techniques. One weakness both technologies share is the 
danger of off-target cleavage. Again, information about ZFNs is more abundant than about 
TALENs. Off-target cleavage of zinc finger nucleases resulting in unwanted genetic changes 
or cytotoxicity has often been reported (Gabriel et al., 2011; Gupta et al., 2011; Pattanayak et 
al., 2011). Notably, not all of the double-stranded breaks could be predicted by in silico 
methods making its discovery even more complicated. As TALENs become more regularly 
used, reports about their off-target effects arise (Hockemeyer et al., 2011). In direct 
comparison of studies using both ZFNs and TALENs for the same target sequence, it is 
reported that off-target-cleavage related cytotoxicity is much lower in TALEN-treated cultures 
(Mussolino et al., 2011). Together with their easier assembly, it seems that most of site-
directed nuclease approaches of the near future would rely on TALENs rather than on ZFNs. 
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Shortly after the introduction of TALENs, another system for double strand break induction 
was established: clustered regularly interspaced short palindromic repeats (Crispr) and their 
Crispr-related Cas nucleases, forming the Crispr/Cas9 system (Bhaya et al., 2011). This 
system is originally part of the adaptive immune system of bacteria and archaea, which uses 
short RNA to direct degradation of alien nucleic acids (Jinek et al., 2012). After modification, 
it has been shown to work with customized guide RNAs, directing the activity of Cas9 
nuclease to a specific sequence in the human genome (Mali et al., 2013). The ease of the 
system is based on its guide RNAs: engineering of the binding motif of a protein is not 
required, as it is possible to directly integrate a short sequence into a targeting plasmid, 
which can easily be done using a quick cloning step. Within a short time, libraries for every 
gene of the human genome were established, making it very easy for everyone to use this 
new technology (Shalem et al., 2014; Zhou et al., 2014). One drawback in comparison to 
TALENS remains: based on its nature, the sequence of the guide RNA is not completely 
unrestricted, as it has to follow a certain pattern of 23 base pairs of the motif GN20GG, 
thereby reducing the possible sites of application in the genome. 
 
5.5 Genetic aberrations in cultivated stem cells and their progeny 
It is not only the use of nucleases that can introduce genomic alterations. The generation of 
the initial pluripotent cell can incorporate damage into the genome, especially if induced by 
viral vectors (Nakagawa et al., 2008; Okita et al., 2007). Even the cultivation of pluripotent 
cells in vitro can lead to the accumulation of alterations as often reported (Howden et al., 
2011; Maitra et al., 2005; Spits et al., 2008). After the generation of neural stem cells, these 
are reported to be more susceptible to other kinds of abnormalities in culture, some of which 
are also found in human tumors of the nervous system (Ben-David et al., 2011; Sartore et al., 
2011). Finally, neural stem cells that have been through all of these protocols are subjected 
to ZFN treatment and clonal selection with toxic components to generate single clones that 
are used for transplantations into mice, where they are left to mature into neurons for several 
months. There are therefore many possibilities, and surely enough time, to develop an 
abnormal genotype. As seen in this study, it is important to carefully monitor the cell 
population gained by the application of double strand breaks for their chromosomal integrity. 
Many clones submitted to SNP analysis had prominent duplications or deletions. The 
selection process used to gain single clones is in part responsible for the enrichment of 
chromosomal aberrations. Clones of lt-NES cells are picked when they are large enough to 
be transferred into the next cell culture dish. This means that clones with a growth advantage 
are automatically the first to be picked, a growth advantage that may result from duplications 
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of oncogenes or deletions of tumor suppressors. This neoplastic enrichment is seen in the 
SNP analysis shown in Fig. 4.8: Clone A was derived from the first round of faster growing 
clones, while clone B was derived from the second round of clone picking, originally slower 
growing. Differences between the two populations could also be seen in culture, as clone A 
was growing faster and the media became acidic quicker. Differentiation into neurons was 
impaired in clone A, and instead the culture kept on proliferating. The same would likely 
happen within a mouse brain after grafting; a population like clone A could lead to overgrowth 
or tumor formation, not only diminishing the experiment but also causing avoidable pain to 
the receiving animal (Wislet-Gendebien et al., 2012). It can be asked if an Illumina chip SNP 
analysis is sufficient to detect all dangerous alterations, as translocations or single base pair 
mutations would not be apparent. Nevertheless, in our study it was sufficient, together with 
observation of the in vitro cultivation, to select for a clone without abnormal growth or 
differentiation behavior. Generally, phenotypic, functional and genetic assays should be 
performed on cells that were treated with nucleases before in vivo use to demonstrate 
whether their biological properties remain suitable for clinical applications. Ultimately, 
populations that are selected for transplantation might have to be sequenced completely, but 
with today’s advances in sequencing technology, such levels of quality control are more and 
more broadly accessible. 
 
5.6 ADK-/- lt-NES cells as an adenosine releasing cell population 
The basic idea of disrupting the adenosine kinase gene was to eliminate the strongest 
metabolizer of adenosine, thus increasing the total amount of adenosine present in the cells, 
which would be secreted into the subcellular space. This secretion into cell culture 
supernatants could be confirmed by using mass spectrometry, but only if the second-most 
important metabolizer, the enzyme adenosine deaminase (ADA), is inhibited with EHNA. The 
secretion of adenosine into media supernatants is not an ideal way to mimic an in vivo 
dispersion of adenosine, which is expected to bind to A1 receptors of host cells before being 
metabolized to inosine by adenosine deaminase. Km values for interaction with A1 receptors 
are at least 5 times lower than for adenosine deaminase (Arch and Newsholme, 1978; Yan et 
al., 2003). In the hippocampus, ADA expression is quite low (Geiger and Nagy, 1986). 
Additionally, inosine is reported to have anticonvulsant properties acting differently from 
adenosine (Ganzella et al., 2011). Therefore the observation that adenosine levels after 
several hours at 37°C are strongly decreased if the adenosine deaminase is not blocked, 
was not surprising. 
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The generation of an ADK-/-/ADA-/- double knockout by starting with an ADA-deficient iPS cell 
line (unpublished data) was also investigated. Despite multiple approaches, no cells could be 
produced (data not shown). Both adenosine kinase and adenosine deaminase metabolize 
adenosine as part of metabolic routes enabling the organism to salvage the degradation 
products of adenosine nucleotides, and recycle them back to nucleotide form. Disrupting both 
major biochemical pathways for adenosine consumption hinders the synthesis of nucleic 
acids and leads to an overload with adenosine, two conditions that seem to be toxic to the 
cells used here. This was also observed while incubating the ADK knock-out cells over more 
than 24h with EHNA, as this also resulted in complete cell death, while wild type cells were 
not affected by EHNA application. 
 
5.7 The effect of grafted ADK-/- lt-NES cells in epileptic animals 
In a kainic acid model of temporal lobe epilepsies, a trend towards less frequent seizure 
events compared to a wildtype control cell population was seen. More experiments are 
needed to conclude whether the ADK knock-out population has a positive effect on seizure 
development in this paradigm. 
In the use of an electric kindling setting, one significantly different parameter between 
adenosine releasing cells, wildtype cells and sham controls was found as the after-discharge 
threshold was significantly increased in animals grafted with ADK-/- cells. Normally, during 
kindling the ADT decreases, making the induction of a seizure easier. At the same time, 
severity and duration of seizure events increase, which is why the method is called kindling; 
the increase in response to small stimuli is similar to the way small burning twigs can 
produce a large fire (Goddard et al., 1969). But what if the stimuli are not small any more but 
have to become bigger to result in an effect? What does such an increase indicate? 
Technically, a higher current was needed to provoke an epileptic seizure – but when a 
seizure was finally initiated it was stronger and lasted longer in these animals. Such 
insulating effects are observed at scar formation, when astrocytic tissue shields the 
stimulation electrode, which in turn can no longer act directly on the surrounding neural 
tissue (Griffith and Humphrey, 2006). Histological analysis of animals of this study after 
kindling did not show any indication of such a scar formation and thus, other explanations 
need to be discussed. Another possibility was that the long grafting tract could have 
damaged the hippocampus and thus led to a state in the buffer-receiving animals which 
could not longer be kindled, while in the cell-grafted mice the transplanted cells could have 
filled the damaged area. Also, as cells were grafted in total volumes of 4-5 µl, intracranial 
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hypertension could have resulted from the procedure and thus might have lead to damage to 
the brain, but also here, no histological indications for such damage could be found. 
The transplantation of wildtype cells increased seizure frequency and duration, which is in 
contrast to previous reports that showed that grafting of “blank” neural stem cells reduces 
susceptibility to seizures in a rat kindling model (Shindo et al., 2010). 
The most important mediator for the anticonvulsive function of adenosine is the A1 receptor, 
whose activation leads to an inhibition of neural activity (Mareš, 2010). It has been reported 
for temporal lobe epilepsy in humans that A1 receptors are lost (Glass et al., 1996) and a 
receptor down-regulation has also been shown to occur during status epilepticus (Hamil et 
al., 2012). In contrast, the function of the stimulating A2A receptor remains controversial, as it 
can favor convulsions in certain conditions (Fukuda et al., 2011; Li and Henry, 1998). 
Reported changes in receptor expressions in kindled animals are also ambiguous, as a 
recent study depicted an increased expression of A1 receptor mRNA in several brain areas 
as well as a decrease in striatal A2A receptor mRNA in rats indicating an adaptive mechanism 
in the brain (Aden et al., 2004). The opposite results, however, were reported in another 
study where a decrease in A1 receptors and increased density of A2A receptor in cortices of 
rats undergoing amygdala kindling or kainate kindling were monitored (Rebola et al., 2005). 
Such changes in receptor expression need a certain amount of time. The length of time 
between grafting and beginning of kindling may be of importance. In the experiments shown, 
lt-NES cells were given 4 weeks to mature into neurons and innervate the host tissue before 
kindling started. Most of the studies using adenosine administration for epilepsy treatment, 
either by sponges, cells or micropumps, were monitored for around just 2 weeks after starting 
of kindling (Boison et al., 1999; Huber et al., 2001; Li et al., 2007b; Szybala et al., 2009; Van 
Dycke et al., 2010; Wilz et al., 2008) This time frame coincided with the dry-run of the sponge 
or the elimination of cells, but also could give a hint that longer time intervals are problematic 
due to other reasons. With a time frame of 4 weeks it is possible that the critical time window 
for significant effects has passed, and the permanently higher adenosine level had finally 
lead to a receptor down regulation, thereby terminating the desired effect before it could be 
seen on the EEG. 
Another explanation could be that the wrong parameters were looked for. The kindling model 
normally uses the same current which was initially high enough to induce a reaction, 
throughout the course of the experiment. If antiepileptic effects were present, they emerged 
by decreased seizure classes and seizure durations over time. In the kindling model used in 
this study, afterdischarge threshold increased, and the used current was subsequently raised 
to again provoke a reaction. Increased afterdischarge thresholds were reported for other 
conditions in the kindling model. After performing kainic acid treatment in rats, kindling of the 
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epileptic animals resulted in a higher ADT, which was interpreted as a result of natural 
protective mechanisms, that the epileptic brain develops to suppress seizure activity 
following the kainate-induced alterations in connectivity and neuronal architecture (Bragin et 
al., 2002). This would indicate that our cell population mimics such protective mechanisms, 
maybe by the adenosine increase. Another example is the increase in ADT seen while 
applying an A1 receptor agonist as anticonvulsive drug (Potschka et al., 1998). Hereby, 
duration and severity of seizures were also not improved after applying higher currents to 
overcome the higher ADT value. Based on mathematical exclusion of all animals with an 
ADT increase of more than 20 %, they declared their drug to be anticonvulsive. Using the 
same calculations with our experiment would result in 77,8 % of animals to be named 
protected from seizures. Another study used adenosine-releasing encapsulated myoblasts 
that were grafted into the lateral ventricle after animals were fully kindled (Güttinger et al., 
2005). Further application of the same electrical current that was used before to kindle the 
rats showed no effect in animals which received a transplant. It is very likely, that here also 
the afterdischarge threshold was strongly increased, although it was not mentioned in the 
study. Using the same paradigm to not increase the currents after kindling started, the 
experiments performed during this study would declare the used ADK-/- lt-NES cells as acting 
anticonvulsively. 
Taken together, the current literature suggests that an increase in afterdischarge threshold 
indicates a lower susceptibility towards seizure initiation. Epilepsy can be seen as the state 
of a neuronal network that shows lower resistance to initial electric stimuli. If larger currents 
and thus larger stimuli are needed to provoke a seizure, they are harder to generate and thus 
less likely to occur by coincidence. It is not wrong to call a procedure that increases the 
energy needed to induce seizures anti-epileptic. As animals in the kindling model show no 
spontaneous seizures, the use of other epilepsy models would be preferred to validate this 
conclusion in a better resemblance to the human clinical picture. 
 
5.8 The immune system and epilepsy 
Many epileptic events lead to neurodegeneration followed by inflammation (Kan et al., 2012). 
Concurrently, proinflammatory stimuli exhibit proconvulsant properties (Auvin et al., 2010). 
This reciprocal amplification is an important promoter of epileptogenesis. To what amount the 
immune response is accountable for the function of epileptic models is of importance, as the 
grafting of human cells into mice makes it either necessary to immunosuppress the recipients 
or to use genetically immunodeficient mouse strains. The first option is not only difficult in 
regards of handling of the animals, as epileptic animals are much more aggressive than 
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normal ones, but  immunosuppressants such as ciclosporin also have an influence on 
epileptogenesis and may also cause seizures by themselves in human patients (Navarro et 
al., 2010; Saner et al., 2010). 
Using immunodeficient mice with Rag2 knockout, two important differences were seen in 
comparison to standard C57/Bl/6 mice. First, kindling was in the beginning not very efficient 
in regard to seizure development, and second, and more importantly, it was not possible to 
generate pilocarpine-induced epileptic animals. BALB/c nude mice in a pilocarpine model 
were reported to be much more vulnerable to status epilepticus (Vignoli et al., 2012) and this 
may also be the reason for the loss of all Rag2-/- animals in the weeks following pilocarpine 
treatment in the experiment performed during this study.  
Overall, the multiple interactions between the immune system and epilepsy add an additional 
degree of complexity to the combination of human cell grafting and animal models of 
epilepsy. 
 
5.9 General conclusion 
This study proved that lt-NES cells are very amenable to genetic manipulation, as shown by 
two different methods. By AAV-mediated targeting, gene correction of the expanded allele of 
ATXN3 with its wildtype variant was performed, resulting in a cell population liberated from its 
pathogenic phenotype. Via ZFN-mediated disruption of the ADK gene, an adenosine-
releasing cell population with potential anti-convulsive qualities was generated. Both 
techniques proved to be very efficient to generate a multitude of monoclonal cell lines if 
combined with a strong selection method. The generated modified lt-NES cells could be 
differentiated into mature neurons and survived after grafting into animals for several months. 
Being an isogenic control population, they will offer a valuable addition to current 
experiments aiming at the deciphering of disease mechanisms and also offer the possibility 
of future cell therapeutic attempts. Applied to patient-derived iPSCs, such techniques offer 




The cell populations established during this study form the basis for further investigations. 
Peculiarly in the neuroscience field, a large fraction of disorders is of late-onset, which - in 
the limited time of cell culture experiments - presumably results in differences that maybe 
cannot be distinguished from background-related variations. Isogenic control lines already 
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set the benchmark for analyses of disease-modeling approaches using iPSC technology, 
especially where high sensitivity is important. 
The indications for antiepileptic activity of adenosine-releasing cells should be addressed in 
further animal experiments with higher number of animals. It is conceivable that both 
localization of the grafts or the neural subtype of the grafted cells have an effect on anti-
epileptic or anti-epileptogenic abilities. Indications that GABAergic interneurons render a 
suitable population for antiepileptic cell therapy suggest to further improve differentiation into 
a more specific interneuron subtype, as most lt-NES cell-derived neurons already are 
GABAergic following the default differentiation protocol (Cunningham et al., 2014). 
The establishment of isogenic control lines of MJD patients allows to conduct a large array of 
comprehensive experiments: The fixed genetic background with differences in only one 
specific locus allows for expression profiling methods like DNA microarrays or RNA-seq with 
much lower background noise and thus higher significance in finding differentially expressed 
genes. The discrimination between disease-related and background effects is of utmost 
importance, considering that approximately 5% of all genes are differently expressed due to 
genetic variation, not even accounting for reprogramming-associated variances (Montgomery 
et al., 2010; Pickrell et al., 2010). 
Gene targeting would also allow generating isogenic populations only expressing the 
pathogenic allele – for the investigation of MJD this could for example be used to explore 
differences in protein-protein interactions compared to physiological ataxin-3 or on 
functionality of the elongated variant by its own. As it is very unlikely that both alleles of 
ATXN3 share the same number of CAG repeats, the investigation of ataxin-3 function 
normally is the result of a combination of two different variants. With the tools developed 
during this study, it should be possible to extent research on ataxin-3 function to different 














Abbreviation Full name 
ADA Adenosine desaminase 
ADK Adenosine kinase 
ADT Afterdischarge threshold 
Ado Adenosine 
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
ATP Adenosin triphosphate 
ATXN3 Ataxin-3 
BMP Bone morphogenic protein 
cAMP Cyclic adenosine monophosphate 
CD Cluster of differentiation 
CNS Central nervous system 
DABCO 1,4-Diazabicyclo[2.2.2]octan 
Dach1 Dachshund homolog 1  
DAPI 4',6-Diamidino-2-phenylindole  
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
DMSO Dimethyl suphoxide 
dNTPs Nucleoside triphosphate 
EB Embryoid body 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFP Enhanced green fluorescent protein 
ER Endoplasmatic reticulum 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
GFAP Glial fibrillary acidic protein 
GMP Guanosine monophosphate 
HD Huntington’s disease 
HEK Human embryonic kidney 
hES cell Human embryonic stem cell 
hPS cell Human pluripotent stem cell 
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Abbreviation Full name 
Ino Inosine 
iPS cell Induced pluripotent stem cell 
IRES  Internal ribosomal entry site 
KA Kainic acid 
LIF Leukemia inhibitory factor 
Ln Laminin 
lt-NES cell long-term self-renewing neuroepithelial stem cell 
MAP Microtubuli-associated protein 
MEF Mouse embryonic fibroblast 
miRNA micro RNA 
MJD Machado Joseph disease 
mRNA messenger RNA 
NE Neuroepithelia 
neoR Neomycin resistance 
NMDA N-Methyl-D-aspartic acid 
PAGE Polyacrylamid gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
PO Poly-ornithine 
puroR Puromycin restance 
RNA Ribonucleic acid 
RT-PCR Reverse-transcriptase PCR 
SCA3 Spinocerebellar ataxia type 3 
SDS Sodium dodecyl sulphate 
SHH Sonic Hedgehog 
siRNA small interfering RNA 
SMAD Mothers against decapentaplegic homolog 
Sox2 SRY-box 2 
SVZ Subventricular zone 




Abbreviation Full name 
TF Transcription factor 
TGFβ Transforming growth factor β 
TI Trypsin inhibitor 
ZFN Zinc finger nuclease 


































Modern stem cell technology has made remarkable progress in recent years with the 
discovery of induced pluripotency, enabling the production of any cell type from any person in 
unlimited quantities, as well as improved protocols for the generation of stable neural stem 
cells to generate all cells of the central nervous system. This forms the base to examine 
neurons derived from patients of neurodegenerative diseases in vitro, allowing elucidation of 
disease mechanisms, as well as to regenerative production of neurons and other cells of the 
CNS. This study investigated two different techniques in order to achieve a specific genetic 
change in human neural stem cells, enabling the generation of modified neurons. A zinc 
finger nuclease (ZFN) attempt was used for the targeted destruction of the adenosine kinase 
gene (ADK) to obtain an adenosine releasing cell population comprising anti-epileptic 
properties. With recombinant adeno-associated virus (AAV), the Machado-Joseph disease 
(MJD) causing prolonged allele of ataxin-3 was replaced with the other allele of normal 
length. The destruction of the ADK gene by frame shifting in course of repairing the ZFN-
induced double-strand break was confirmed by sequencing and Western blot analysis and 
led to a strong increase in adenosine efflux in neural stem cells, which was maintained after 
differentiation into neurons. Use of this cell population in mouse models of epilepsy to test 
the anticonvulsant properties have so far not led to a clear result. While due to small animal 
quantities in a kainate-induced model only a statistically non-significant trend toward reduced 
seizure frequency in animals with ADK-/- cells compared to wild type cells could be observed, 
in a model of electrical seizure induction (Kindling) animals showed a strongly increased 
resistance to the amount of current necessary to induce a seizure. After AAV-mediated 
exchange of the pathogenic ATXN3-allele against the physiological length, PCR and Western 
blot analysis confirmed the loss of extended transcript and protein variants in the cells. 
Following Cre-mediated removal of the selection cassette, a normal protein variant was 
transcribed from both alleles. MJD patient-derived neurons showed the formation of insoluble 
microaggregates following glutamate-induced activation. This aggregation was no longer 
detectable after gene correction. The method used consequently led to neurons, which no 
longer showed the disease phenotype. Both techniques used were highly efficient and 
produced very few false positive clones. These results indicate that neural stem cells are an 
ideal population for genetic manipulation and that the techniques used provide new 
perspectives for the study of disease mechanisms in the culture dish as well as open the field 





Die moderne Stammzell-Technologie hat in den letzten Jahren erstaunliche Fortschritte 
gemacht, insbesondere durch die Entdeckung der induzierten Pluripotenz, welche 
ermöglicht, von jedweder Person Zellen beliebiger Gewebe in unbegrenzten Mengen 
herzustellen. Zusätzlich erleichtern Protokolle, welche die Generierung von stabilen neuralen 
Stammzellpopulation aus diesen pluripotenten Zellen ermöglichen die Generierung von 
Zellen des Zentralnervensystems maßgeblich. Damit liegt das Werkzeug bereit, Neurone von 
Patienten neurodegenerativer Erkrankungen in der Zellkultur zu untersuchen um 
Krankheitsmechanismen zu erklären als auch regenerativ Neurone und andere Zellen des 
Gehirns herzustellen, um den Verlust dieser Zellpopulationen während der Erkrankung 
auszugleichen. 
Diese Studie untersucht zwei verschiedene Techniken, um eine gezielte genetische 
Veränderung in neuralen Stammzellen zu erreichen, welche die Generierung veränderter 
Neurone ermöglicht. Zum einen wurden Zinkfinger-Nukleasen (ZFN) zur gezielten Zerstörung 
des Adenosinkinase-Gens (ADK) verwendet, um eine Adenosin-ausschüttende 
Zellpopulation zu erhalten, die antiepileptische Eigenschaften aufweist. Des weiteren wurde 
mittels rekombiniertem Adeno-assoziierten Virus (AAV) das Machado-Joseph Krankheit 
(MJD)-auslösende, verlängerte Allel von Ataxin-3 gegen das andere Allel normaler Länge 
ausgetauscht. 
Die Zerstörung des ADK-Gens durch Verschieben des Leserahmes bei der Reparatur des 
ZFN-induzierten Doppelstrangbruches konnte mittels Sequenzierung und Western Blot 
gezeigt werden und bewirkte eine starke Erhöhung des Adenosin-Ausstoßes in neuralen 
Stammzellen, welcher auch nach Differenzierung zu Neuronen und Astrozyten erhalten blieb. 
Verwendung der Zellpopulation in Epilepsiemodellen der Maus zur Prüfung der 
antikonvulsiven Eigenschaften führten bislang zu keinem eindeutigen Ergebnis. Während 
aufgrund kleiner Tiermengen in einem Kainat-induziertem Modell lediglich ein statistisch nicht 
signifikanter Trend in Richtung reduzierter Anfallshäufigkeit in Tieren mit ADK-/- Zellen im 
Vergleich zu wildtypischen Zellen beobachten werden konnte, zeigten Tiere in einem Modell 
von elektrischer Anfallsinduktion (Kindling) einen stark erhöhten Widerstand gegenüber der 
notwenigen Stromstärke, die nötig war um einen Anfall zu induzieren. 
Nach AAV-vermittelten Austausch des pathogen ATXN3-Alleles gegen eine physiologische 
Länge waren durch PCR und Western Blot keine verlängerten Transkript- und 
Proteinvarianten in den Zellen mehr auffindbar. Durch Cre-vermittelte Entfernung der 
Selektionskassette wurde von beiden Allelen die normale Proteinvariante transkribiert. Von 
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MJD-Patienten abgeleitete Neurone zeigten zuvor die Bildung von unlöslichen 
Mikroaggregaten nach Glutamat-induzierter Aktivierung. Diese Aggegratbildung war nach der 
Genkorrektur nicht mehr nachweisbar. Die verwendete Methode führte folglich zu Neuronen, 
die keinen krankheitstypischen Phänotyp mehr zeigten. 
Beide verwendeten Techniken waren hocheffizient und erzeugten nur  sehr wenige falsch-
positive Klone. Diese Ergebnisse zeigen, dass neurale Stammzellen eine ideale Population 
zur genetischen Manipulation sind und die verwendeten Techniken neue Perspektiven für die 
Erforschung von Krankheitsmechanismen in der Kulturschale liefern als auch die Möglichkeit 
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